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Abstract 
 Methionine is an indispensable amino acid in the diet of neonates and has a 
metabolic role in the synthesis of creatine, phosphatidylcholine (PC) as well as 
protein synthesis and other transmethylation reactions. Creatine synthesis consumes 
significant amounts of arginine (a conditionally essential amino acid) and methionine, 
while PC requires methionine for its synthesis. Total parenteral nutrition (TPN) is 
typically marginal in these amino acids, and devoid in creatine. Therefore, our 
objective was to quantify the partitioning of methyl groups among transmethylation 
reactions and the sparing effect of dietary creatine and GAA on protein synthesis. 
Adequate supply of dietary methionine resulted in significantly greater hepatic 
fractional synthesis rate (FSR) of PC. Furthermore, GAA supplementation increased 
FSR of creatine by approximately 175%, but only when adequate dietary methionine 
was supplied. Moreover, piglet weight gain was similar to that of piglets receiving 
adequate arginine, suggesting arginine was spared for growth. Overall, supplemental 
GAA could be considered as a novel TPN ingredient to increase the synthesis of 
creatine and spare arginine for growth, but only when adequate methionine is 
provided. 
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1. Introduction 
1.1 Total Parenteral Nutrition (TPN) 
 Total parenteral nutrition (TPN) was first introduced clinically in the early 1970’s. 
Since TPN was first introduced, it has revolutionized how intestinal disease and 
dysfunction are treated. TPN is commonly used during times of intestinal distress, such as 
necrotizing enterocolitis (NEC), short bowel disease or feeding intolerance experienced 
by premature infants (Johnson, 2014). Due to the underdevelopment of the gut when an 
infant is born premature, it is very difficult to meet their nutritional needs as they have 
limited energy reserves (Brunton, Ball, & Pencharz, 2000). Feeding intolerances often 
develop and caloric intake is restricted, leading to growth retardation. TPN has allowed 
for increased survival and growth in pre-term infants over the last number of decades as 
an alternative method of nutrient delivery (Schutzman, Porat, Salvador, & Janeczko, 
2008). 
 
1.1.1 TPN Dietary Composition 
 TPN consists of all essential macro- and micro-nutrients. Carbohydrates are 
provided as a monosaccharide in the form of dextrose. Protein is commonly provided as 
crystalline amino acids with elevated essential to non-essential amino acid ratio, while 
cysteine is commonly added to parenteral nutrition (PN) solutions for neonates to prevent 
impairment of protein synthesis (Johnson, 2014a). It is estimated that protein retention 
during PN is approximately 70% (Schutzman et al., 2008). Therefore, in a clinical setting, 
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a range of approximately 3-4 g/kg/day of amino acids is recommended to promote growth 
in a premature infant (Johnson, 2014a). Fat is delivered in the diet as 20% lipid 
emulsions, commonly provided as a soybean oil emulsion in the form of Intralipid 
(Schutzman et al., 2008). Lipids are an important energy source for the neonate. It 
provides premature infants high energy for fat deposition during growth and spares 
energy from amino acids for protein synthesis (Johnson, 2014a). The recommended 
caloric intake for neonates receiving TPN is approximately 85-127 kcal/kg/day. This 
caloric intake is estimated to help the infant grow at approximately 15 g/kg/day (Johnson, 
2014a). Understanding the energy requirements for the neonate is essential when 
administering TPN. 
 Micronutrients are provided in TPN as electrolytes, trace minerals and complex 
multiple vitamin solutions. These micronutrients are essential to the proper growth and 
development of the neonate (Johnson, 2014b). Research continues to refine PN solutions 
to alleviate complications associated with TPN, while increasing growth rates of infants. 
 
1.1.2 TPN Drawbacks 
 Prolonged administration of TPN has been shown to lead to negative effects in 
both neonates and adult patients (Schutzman et al., 2008). One of the major drawbacks of 
TPN as an intervention method is gut atrophy. TPN by-passes first-pass splanchnic (ie. 
gut and liver) metabolism, and therefore does not utilize the gut for the digestion and 
absorption of essential nutrients. Niinikoski and colleagues demonstrated that only 8 
hours after the introduction of TPN in three-week-old piglets, portal and superior 
mesenteric artery (SMA) blood flow decreased by more than 30% in comparison to 
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enterally fed pigs. These findings demonstrated the detrimental effects of TPN on the 
integrity of the gut, resulting in villous atrophy and decreased protein synthesis after 48 
hours (Niinikoski et al., 2004). Gut atrophy from prolonged TPN can become problematic 
for the metabolism in the neonate. For example, the synthesis of the conditionally 
essential amino acid arginine occurs in the gut; and therefore, its synthesis becomes 
impaired with gut atrophy (Brunton et al., 2000). 
 Gut atrophy can lead to more serious conditions. NEC is a gastrointestinal 
infection resulting in mucosal inflammation and disruption in gut integrity. NEC is 
commonly seen in low birth weight infants and can result in intestinal perforation, 
surgery, and death (Dinesh et al., 2014). TPN affects the maturity of the gut and in 
piglets, introduction of formula feeding after TPN can lead to gut dysfunction and NEC. 
On the other hand, colostrum milk improved gut maturity and decreased the likelihood of 
NEC after administration of TPN (Bjornvad et al., 2008). Moreover, further research 
needs to be conducted to determine the optimal volume and rate of introduction of enteral 
feeds for premature infants transitioning from TPN. Gut atrophy and intestinal damage 
from disease such as NEC also down-regulate the synthesis of arginine (Brunton et al., 
2000). As early as 1997, decreased arginine concentrations in pre-term infants were 
identified during the time of diagnosis of NEC (Zamora et al., 1997). Moreover, this 
observation led to research on the possible benefits of arginine supplementation for the 
prevention of all stages of NEC in premature infants (Amin et al., 2002). 
 Another problematic risk factor of TPN is prolonged implantation of central 
venous lines for the administration of TPN. The longer a patient is receiving TPN, the 
greater the likelihood of infection or vascular thrombosis (Schutzman et al., 2008). 
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Although from a clinical standpoint, the likelihood of infection is reduced with proper 
dressing techniques at the site of administration (Costello et al., 2008). The benefits 
associated with the administration of TPN during times of gastrointestinal distress 
outweigh the risks, since the survival rate of premature infants continues to increase 
(Schutzman et al., 2008). 
 
1.1.3 Parenteral Nutrition-Associated Liver Disease (PNALD) & Cholestasis 
 The most common complication associated with TPN administration in neonates 
is the development of parenteral nutrition-associated liver disease (PNALD), that 
commonly presents as liver cholestasis (Kelly, 1998). TPN-induced liver cholestasis is 
characterized by bile duct regeneration, portal inflammation and fibrosis (Guglielmi et al., 
2008). Over the past number of years, much research has been conducted to prevent the 
onset and reduce the severity of PNALD, but it continues to be a consequence with 
prolonged TPN administration. Schutzman and colleagues reported that 8-50% of 
extremely low birth weight (ELBW) infants receiving TPN for only 2 weeks 
demonstrated signs of biochemical cholestasis. Moreover, the incidence spiked to 
approximately 90% of ELBW infants receiving TPN for more than 90 days (Schutzman 
et al., 2008).  
 Many risk factors are associated with the development of TPN-induced liver 
cholestasis. These risk factors include liver dysfunction, sepsis, infection and nutritional 
deficiencies (Vlaardingerbroek et al., 2014). At this point in time, there is no definitive 
clinical method to prevent or alleviate liver cholestasis from prolonged TPN other than 
termination of administration. Recent research on prevention and reversal of PNALD has 
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focused on the lipid component of PN. Soybean oil has been the main source of lipids in 
commercial emulsions used in TPN for decades, but recent research suggests that this 
could be the cause of TPN-induced cholestasis. Soybean oil is high in phytosterols which 
have been shown to damage the biliary tract and disrupt bile flow (Clayton et al., 1998). 
Recently, Vlaardingerbroek and colleagues demonstrated that a 15% fish oil lipid 
emulsion protected against PNALD in pre-term piglets in comparison to TPN containing 
soybean oil lipid emulsion (Vlaardingerbroek et al., 2014). However, unlike Clayton et 
al., they found that phytosterols were not associated with the development of PNALD. 
These results provide evidence that lipid emulsions in TPN require further research to 
possibly prevent or alleviate TPN-induced cholestasis in pre-term infants. 
 
1.2 Creatine Biosynthesis 
 Creatine biosynthesis is a major synthesis pathway that occurs in mammals and is 
a major consumer of labile methyl groups (Brosnan et al., 2009). Creatine synthesis 
primarily occurs in the liver and kidney (Wyss & Kaddurah-Daouk, 2000). In the kidney, 
arginine transfers an amidino group to glycine to form guanidinoacetate (GAA) and 
ornithine via the enzyme arginine:glycine amidinotransferase (AGAT). GAA is then 
transported to the liver and methylated by S-adenosyl methionine (SAM) via the enzyme 
guanidinoacetate methyltransferase (GAMT). One labile methyl group is transferred to 
GAA resulting in creatine and S-adenosyl homocysteine (SAH) (Brosnan & Brosnan, 
2016). Creatine can then be transported to other tissues with high energy demand, such as 
brain and skeletal muscle. Creatine itself can be phosphorylated via creatine kinase to 
phosphocreatine which is used as an energy buffer to convert adenosine triphosphate 
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(ATP) to adenosine diphosphate (ADP) in a reversible reaction (Wyss & Kaddurah-
Daouk, 2000). This rapid conversion and regeneration of ATP has made creatine 
supplementation a popular ergogenic aid in the fitness world. 
 The two enzymes involved in creatine biosynthesis, AGAT and GAMT, in some 
cases do not function properly due to a result of an inborn error of metabolism. As a 
result, an inborn error in the function of AGAT and GAMT may result in creatine 
deficiency in the brain and muscle. An inborn error in GAMT can lead to mental 
retardation at an early age (Sykut-Cegielska et al., 2004). However, it should be noted 
that large doses of creatine supplementation in infants suffering from AGAT or GAMT 
deficiency will normalize creatine levels if started at birth (Braissant et al., 2011; Schulze 
& Battini, 2007). Moreover, the success of this therapy has been demonstrated in AGAT 
knockout mice by Nabuurs and colleagues. Mice fed a creatine-free chow diet 
demonstrated disturbed muscle energy metabolism that could be rescued by 
supplementation with dietary creatine (Nabuurs et al., 2013). The clinical severity of 
these inborn errors of AGAT or GAMT in infants and the need for early intervention to 
prevent lifelong damage raises the question of whether infants should be screened at birth 
for defects in creatine synthesis. 
 
1.2.1 Amino Acids & Metabolites Involved in Creatine Synthesis 
1.2.1.1 Glycine 
 Glycine is a non-essential amino acid in the neonate and the adult, except in avian 
species where it is considered essential (Baker, 2009). Glycine can be synthesized via an 
inter-organ pathway primarily involving the liver and kidney (Wang et al., 2013). It is 
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synthesized from serine, threonine, choline, or hydroxyproline. Although it is non-
essential, glycine plays many important roles such as the synthesis of protein and 
glutathione (GSH), conjugation of bile acids in mammals and in our case most 
importantly, de novo synthesis of creatine (Vlaardingerbroek et al., 2011). As described 
above, glycine’s role in creatine synthesis occurs in the kidney. Glycine accepts an 
amidino group from arginine via the enzyme AGAT. It has been estimated that glycine 
accounts for approximately 11.3% of total protein in the piglet (Wu et al., 1999). 
Moreover, Brosnan et al. estimated that the glycine used for creatine synthesis only 
amounts to an equivalent of approximately 2.7% of net glycine incorporated into protein 
(Brosnan et al., 2009). 
 Aside from creatine synthesis, glycine plays a major role in protein synthesis and 
growth in the neonatal piglet. It has been estimated that protein synthesis accounts for 
approximately 80% of whole body glycine needs by animals, including piglets (Wu et al., 
2004). Moreover, because of these high demands for protein synthesis and growth, there 
is the question of whether de novo synthesis of glycine can fully meet the demands of the 
growing neonate. Recently, strong evidence has been published to suggest that glycine 
synthesis is inadequate to meet the energy and growth demands of the growing neonatal 
piglet, and therefore glycine should be considered a dietary essential amino acid (Rezaei 
et al., 2013). 
 Glycine also has a major role in the synthesis of GSH, a major intracellular 
antioxidant, especially in early development when GSH pools are expanding 
(Vlaardingerbroek et al., 2011). Under certain circumstances in the neonate, in particular 
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during critical illness, it may be necessary to increase dietary glycine to maintain 
adequate synthesis of GSH, to prevent further illness and complication. 
 
1.2.1.2 Arginine 
 Arginine is a conditionally essential amino acid depending on the stage of 
development (Dinesh et al., 2014). Arginine plays a major role in the synthesis of creatine 
by transferring an amidino group to glycine to make GAA via AGAT, as described above. 
Along with creatine, arginine plays a role as a precursor for the synthesis of other 
important amino acids and molecules such as proline, ornithine, polyamines and nitric 
oxide (NO). Furthermore, arginine plays a role in the secretion of important hormones 
including growth hormone, insulin, prolactin and glucagon (Vlaardingerbroek et al., 
2011). 
 
a. Arginine de novo Synthesis in Adults 
 Arginine synthesis differs between the growing neonate and the adult. In adults 
and most other mammals, arginine is considered a non-essential amino acid and is 
synthesized primarily through the intestinal-renal axis (Brosnan & Brosnan, 2004). In the 
small intestine, dietary arginine, glutamine, glutamate and proline are converted to 
citrulline through a sequential set of reactions and released into the portal blood. 
Circulating citrulline is primarily taken up by the kidney where two major enzymes, 
argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL), convert citrulline 
to arginine for release back into circulation (Brosnan & Brosnan, 2004). 
 The importance of the intestine in the synthesis of citrulline and arginine is further 
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emphasized by the localization of three major enzymes responsible for the conversion of 
glutamine, glutamate and proline to citrulline. These are pyrroline-5-carboxylate (P5C) 
synthase, proline oxidase, and N-acetylglutamate (NAG) synthase. The enterocyte is the 
only mammalian cell type to express all three of these enzymes (Flynn & Wu, 1996). It 
should be noted that the rate of arginine synthesis in humans depends on the delivery of 
citrulline to the kidney and not on the dietary availability of arginine (Castillo et al., 
1994). Humans with functional kidneys demonstrate high rates of arginine synthesis from 
both endogenous and exogenous citrulline (Brosnan & Brosnan, 2004). Furthermore, it 
has been demonstrated that normal functioning kidneys synthesize approximately 1.75 
g/day of arginine, while patients with chronic renal insufficiency still produce 
approximately 0.7 g/day of arginine (Tizianello et al., 1980). In context, synthesis of 2 g 
arginine/day is compared to approximately 4-5 g/day consumed in a typical Western diet 
(Brosnan & Brosnan, 2004). These findings demonstrate the importance of the intestinal-
renal axis on the synthesis of arginine in humans and mammals. 
 
b. Arginine de novo Synthesis in Neonates 
 In the neonate, arginine is considered a conditionally essential amino acid 
important for growth and many metabolic processes (Dinesh et al., 2014). Unlike the 
adult, neonatal arginine synthesis is localized and primarily occurs in the enterocytes of 
the gut (Vlaardingerbroek et al., 2011). Although the neonate is capable of synthesizing 
arginine, this is considered inadequate to meet the demands of the growing neonate; 
therefore, arginine is considered a conditionally essential amino acid (Dinesh et al., 
2014). 
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 Unlike the adult, arginine is not synthesized in the intestinal-renal axis. But, like 
the adult, arginine is the precursor for the synthesis of NO (Vlaardingerbroek et al., 
2011). Playing an important role in immune and vasodilator activities, NO is an important 
molecule for the development of the neonate. In 2005, Fu and colleagues found that 
animal models of small intestine ischemia/reperfusion demonstrated increased intestinal 
blood flow due to increased NO when supplemented with arginine (Fu et al., 2005). 
These findings demonstrate the important homeostatic role between maintaining gut 
integrity and arginine synthesis in the growing neonate. 
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Figure 1.1: Arginine Synthesis in the Neonatal Gut (Adapted from: Vlaardingerbroek 
et al., 2011). 
ARG, arginine; CIT, citrulline; GLN, glutamine; GLU, glutamate; ORN, ornithine; PRO, 
proline; P5C, 1-pyrrolline-5-carboxylic acid; TCA, tricarboxylic acid. 
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c. Arginine Requirement in Neonates 
 Because arginine is a conditionally essential amino acid in the growing neonate, 
the neonatal arginine requirement is dependent on the stage of development. During early 
development, energy demands are high due to high protein turnover (Dinesh et al., 2014). 
For example, as piglets get older, the dietary arginine requirement decreases. Piglets at 
approximately 4 kg body weight require 2.4% of their crude protein intake as arginine 
while 100 kg pigs only require 1.4% (Ball et al., 2007). The National Research Council 
(NRC) estimates the arginine requirement of growing piglets at 0.40 g/kg body 
weight/day (National Research Council, 1998). However, findings suggest that a 
minimum arginine intake of 0.20 g/kg/day of arginine is required to avoid 
hyperammonemia in piglets (Wilkinson et al., 2004). Another estimate using a factorial 
approach concluded that one-week-old piglets have an arginine requirement of 
approximately 1.1 g/kg/day to meet whole body needs, compared to the arginine intake 
from sow’s milk which is estimated at 0.42 g/kg/day (Wu et al., 2004). Therefore, the 
neonatal piglet relies substantially on de novo synthesis to meet the arginine requirement. 
Although the NRC requirement has been established for growing piglets, recent findings 
have suggested that arginine supplementation increases the rate of growth in neonates. In 
2004, 7- to 21-day-old piglets supplemented with 0.2% and 0.4% arginine in milk 
replacer demonstrated improved weight gains of 28% and 66%, respectively, in 
comparison to the control group fed arginine at the concentration in sow milk (Kim & 
Wu, 2004). 
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d. Arginine Requirement & de novo Synthesis during TPN 
 Prolonged usage of TPN has a significant impact on gut integrity and growth in 
the neonate. Gut atrophy has been shown to result in lower synthesis of arginine in 
neonatal piglets (Bertolo et al., 2003). Therefore, the arginine requirement for neonates 
during TPN is higher than that for neonates receiving breast milk or enteral diets. 
Arginine concentrations in PN solutions range from as high as 12.3 g/100 g amino acids, 
to as low as 4.7 g/100 g amino acids (Vlaardingerbroek et al., 2011). Moreover, in 
commercially available PN solutions, the arginine concentration is more than any other 
conditionally essential and non-essential amino acid. Studies on determining the optimum 
arginine concentration in PN solutions rely on the balance between maximizing growth 
and decreasing the likelihood of PNALD with high amino acid intake (Johnson, 2014a). 
The effect of prolonged administration of TPN to neonates on arginine status has been 
investigated by studying the role of dietary proline in arginine synthesis. 
 In 1999, Brunton et al. administered a complete TPN diet for 1 week to piglets, 
and then administered a PN solution that was complete except devoid in arginine. Within 
hours, this diet led to arginine deficiency as demonstrated by severe hyperammonemia 
(Brunton et al., 1999). When proline (a precursor of arginine) was also removed from the 
diet, these effects were exacerbated. However, the same study was performed using 
enteral diets and arginine deficiency was partially ameliorated as proline was converted to 
arginine by the intact gut. This study outlines the important role the gut plays in the de 
novo synthesis of arginine from proline in neonates and demonstrated the effect of TPN-
induced gut atrophy on the rate of arginine synthesis. Using an isotope tracer study, the 
conversion of proline to arginine was estimated at 17% when proline was introduced into 
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the small intestinal lumen, but when first pass metabolism was by-passed, the conversion 
rate was negligible (Bertolo et al., 2003). Prolonged TPN administration in the neonate 
leads to a significant impact on first-pass metabolism and de novo synthesis of arginine. 
Therefore, the length of exposure to PN and concentration of arginine within PN solutions 
should be considered when neonates require TPN. 
 
1.2.1.3 Guanidinoacetate (GAA) 
 Guanidinoacetate (GAA) is synthesized in the kidney from arginine and glycine 
via the enzyme AGAT, as described above (Brosnan & Brosnan, 2016). GAA is primarily 
taken up by the liver and readily converted to creatine via GAMT. Creatine is used by the 
body for high energy demand processes and has been extensively studied as an ergogenic 
aid for athletes to increase performance in high-intensity sports (Wyss & Kaddurah-
Daouk, 2000). Less is known about GAA’s effect as a supplement to promote growth and 
creatine synthesis. A recent human study in 2014 demonstrated a dose response to GAA 
supplementation on GAA and creatine concentrations in plasma (Ostojic et al., 2014). 
That study demonstrated GAA’s possible effects including upregulating creatine 
synthesis to provide excess for creatine stores for energy metabolism. Those findings 
were supported by research from our group, which found that GAA supplementation to 
young pigs was better than dietary creatine at increasing creatine concentrations in 
hepatic and muscle tissues (McBreairty et al., 2015). However, as our group noted, the 
higher conversion of GAA to creatine leads to an increased consumption of available 
methyl groups. Therefore, dietary GAA supplementation may place a burden on available 
methyl groups and affect other important transmethylation reactions, including PC and 
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protein synthesis. 
 An abnormality in GAMT activity may lead to GAA toxicity and possible mental 
retardation in neonates. Therefore, these findings suggest that GAA supplementation may 
have possible toxic side effects. To asses this in humans, Ostojic et al. demonstrated that a 
6-week supplementation of oral GAA in adults did not lead to any significant negative 
physiological effects (Ostojic et al., 2013). However, hepatocytes isolated from chow-fed 
rats exposed to various concentrations of GAA in vitro demonstrated higher caspase-3 
activity, which is an indicator of apoptosis and cell death (Kharbanda et al., 2014). 
Further research is needed to determine whether GAA supplementation has toxic side 
effects at specific concentrations, particularly in growing animals and humans. 
 
1.2.1.4 Methionine 
 Methionine is the only essential sulfur-containing amino acid and is required in 
the diet in both adults and growing neonates. Methionine also plays a major role in many 
transmethylation reactions (Finkelstein et al., 1988). In the cell, methionine is adenylated 
to SAM via the enzyme S-adenosylmethionine synthetase, also known as L-methionine S-
adenosyltransferase (MAT). SAM acts as a universal methyl donor for over 100 
transmethylation reactions (Stead et al., 2006). Methionine is also the major source of 
cysteine and taurine. Cysteine is the limiting amino acid for the synthesis of glutathione, 
an important antioxidant for the cell, while taurine is also important for normal cell 
function (Vlaardingerbroek et al., 2011). Methionine’s role in many major biological 
processes results in the synthesis of homocysteine. Moreover, folate also plays a role in 
methionine metabolism via the remethylation of homocysteine with 5-
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methyltetrahydrofolate (5-MTHF) via the enzyme methionine synthase (MS) (Bertolo & 
McBreairty, 2013). Methionine’s involvement in many transmethylation reactions and 
biological processes demonstrates its importance biochemically, so it is not surprising that 
it is a principal metabolite of investigations into cardiovascular diseases (Durand et al., 
2001). 
 
a. Methionine Requirement in Neonates 
 Methionine plays an important role in transmethylation reactions and protein 
synthesis during early development when growth is at a high rate. Therefore, it is 
important to ensure the neonate receives the optimum amount of methionine in their diet 
without excessively exceeding the requirement, due to risk factors associated with high 
levels of methionine intake (Garlick, 2006). The WHO/FAO/UNU consultation has 
estimated the methionine intake based on breast milk to be the optimal nutrition for 
infants < 6 months of age, which is 28 mg/kg/day (WHO/FAO/UNU, 2007). 
Interestingly, Huang et al. have more recently used the indicator amino acid oxidation 
technique to determine the methionine requirement in newborn infants, and reported it to 
be ~30% higher than that provided in human milk, at 38 mg/kg/day, even though cysteine 
was provided in excess (Huang et al., 2012). As the infant grows and matures, less 
methionine is required for transmethylation reactions and protein synthesis. As 
demonstrated by Humayun and colleagues, the methionine requirement is lowered to 
approximately 6.55 mg/kg/day in school-aged children, in the presence of cysteine 
(Humayun et al., 2006). 
 It has been estimated that the equivalent of 35% of dietary methionine intake is 
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consumed for de novo creatine synthesis in neonatal piglets (Brosnan et al., 2009). 
Methionine’s role in many major transmethylation reactions, including creatine 
biosynthesis, only further emphasizes the importance of determining the optimal 
methionine requirement in the neonate 
 
b. Transmethylation Reactions 
 As mentioned above, a substantial proportion of methionine in the neonate is used 
for transmethylation reactions. These reactions include, but are not limited to, creatine 
biosynthesis, DNA methylation, phosphatidylcholine (PC) synthesis, protein methylation, 
polyamine and carnitine synthesis, betaine and choline synthesis, and sarcosine synthesis 
(Bertolo & McBreairty, 2013). It has been estimated that creatine synthesis consumes 
approximately 70% of labile methyl groups in adults (Brosnan et al., 2009), although PC 
synthesis is also a major consumer of methyl groups. The distribution of dietary 
methionine and labile methyl groups between protein synthesis and transmethylation 
pathways in the neonate needs further investigation as variations in dietary methionine 
can limit available methionine (Bertolo & McBreairty, 2013). 
 
i. Phosphatidylcholine Synthesis 
 Phosphatidylcholine is the major phospholipid component of all lipoproteins and 
is required for lipoprotein assembly and secretion. PC is synthesized via two major 
pathways: the CDP-choline pathway and the phosphatidylethanolamine N-
methyltransferase (PEMT) pathway (Cole et al., 2012). The ubiquitous CDP-choline 
pathway, more commonly known as the Kennedy pathway, contributes the majority of PC 
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to the pool and synthesizes PC via three enzymatic steps, converting choline to PC 
(Kennedy & Weiss, 1956). The PEMT pathway, which is localized to the liver, 
contributes approximately 30% of total PC and is SAM-dependent (Reo et al., 2002; 
Sundler & Akesson, 1975) Phosphatidylethanolamine (PE) is converted to PC in a three 
step reaction via PEMT requiring three labile methyl groups (Cole et al., 2012).  
 Although PEMT activity only provides 20-40% of total PC, both the PEMT and 
the Kennedy pathway work synergistically. It has been shown that when PEMT is 
inhibited, PC synthesis is three-fold higher via the Kennedy pathway. Moreover, mice 
receiving a diet deficient in choline have an up-regulation of PEMT activity and the PC 
and choline are supplied through the PEMT pathway (Vance et al., 1997; Walkey et al., 
1998) These findings demonstrate the coordination between pathways to ensure adequate 
PC and choline are supplied. The percentage of labile methyl groups consumed for PC 
synthesis is still disputed. Previously, results suggested that PEMT activity only 
consumes approximately 15% of total SAM (Mudd & Poole, 1975). Whereas, recent 
findings showed that the deletion of PEMT in mice causes a 50% decrease in plasma 
homocysteine (Noga & Vance, 2003). These findings suggest that PEMT consumes more 
than 15% of SAM due to the large decrease in plasma homocysteine. More research is 
needed to quantify the burden of PEMT on methyl groups. 
 
ii. DNA Methylation 
 DNA methylation also consumes labile methyl groups. DNA methyltransferase 
(DNMT) transfers a methyl group to cytosine residues in cytosine-phosphate-guanine 
(CpG) dinucleotides of DNA and converts SAM to SAH. Although DNA consumes 
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significantly smaller amounts of labile methyl groups than creatine or PC (McBreairty et 
al., 2013), it can still have a significant effect on epigenetic changes, – the heritable 
modification of gene expression without the alteration of a genetic sequence, usually in 
early development (Waterland, 2006). Dietary availability of methyl groups can also 
affect DNA methylation. For example, animals fed a methyl-deficient diet resulted in 
hypomethylated DNA (Wainfan et al., 1989). Moreover, methionine supplementation 
during early development can lead to increased methylation at certain genes and cause 
permanent changes in DNA expression (Waterland & Jirtle, 2003) 
 Although dietary methyl supplementation can change DNA methylation, it is still 
unclear whether high methionine supplementation induces DNA hyper- or hypo-
methylation (Waterland, 2006). It is possible that methionine’s interaction with the 
transsulfuration pathway via homocysteine is a major factor directing global DNA 
methylation. Higher levels of homocysteine are linked to higher intracellular levels of 
SAH, and therefore a lower SAM/SAH ratio. The intracellular increase in concentrations 
of SAH have been linked to tissue specific changes in DNA methylation. For example, 
higher plasma SAH concentrations were associated with lower global DNA methylation 
in human leukocytes (Yi et al., 2000). On the other hand, there have been other studies 
disputing the relationship between tissue specific elevation in SAH concentrations and 
decreases in global DNA methylation (Heil et al., 2007).  
 Nutritional supplementation of methionine or methyl groups appears to have a 
significant effect on global DNA methylation, with tissue specificity, but the 
consequences of supplementing high methionine and its effects on DNA methylation 
warrant further investigation. 
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c. Remethylation & Transsulfuration 
 Unlike many other amino acids, methionine can be recycled through 
remethylation of homocysteine. As previously discussed, methionine is transmethylated 
via MAT to generate the universal methyl donor SAM, which subsequently generates 
SAH after donating its methyl group (Stead et al., 2006). SAH is then hydrolyzed to 
homocysteine and adenosine by SAH hydrolase. Homocysteine can then be remethylated 
to methionine via one of two major pathways via methionine synthase (MS) or 
betaine:homocysteine methyltransferase (BHMT). MS is a vitamin B12-dependent 
enzyme which uses 5-methyl-tetrahydrofolate (5-MTHF) as a methyl donor for 
homocysteine’s conversion to methionine and reproduces tetrahydrofolate (THF). BHMT 
uses betaine, a product of choline oxidation, as a methyl donor to generate methionine 
and dimethylglycine (DMG) (Finkelstein, 1998).  
 Lower activities of both MS and BHMT have been linked with increased 
concentrations of circulating plasma homocysteine (Schalinske & Smazal, 2012). 
Although methionine is readily trans- and remethylated, methionine can still undergo 
complete catabolism. This occurs in an irreversible reaction where homocysteine is 
converted to cysteine via the transsulfuration pathway. Homocysteine conversion occurs 
in a two-part reaction via two B6-dependent enzymes: cystathionine-b-synthase (CBS) 
and cystathionine-g-lyase (CGL) (Schalinske & Smazal, 2012). There is evidence to 
suggest that the upregulation of CBS activity is an important factor when determining 
and/or controlling homocysteine levels (Wang et al., 2004), and in turn may lower the 
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risk of cardiovascular and linked metabolic diseases, which are usually associated with 
high plasma homocysteine levels (Schalinske & Smazal, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 22	
 
Figure 1.2: Methionine Cycle and Transmethylation Partitioning (Adapted from: 
Strauss et al., 2015). 
5Me-THF, 5-methyltetrahydrofolate; AHCY, AdoHcy hydrolase; BHMT, 
betaine:homocysteine methyltransferase; CBS, cystathionine β-synthase; DMG, 
dimethylglycine; GAA, guanidinoacetate; GAMT, guanidinoacetate methyltransferase; 
GNMT, glycine N-methyltransferase; MAT, methionine adenosyltransferase; MS, 
methionine synthase; MTN, more than 100 other methyltransferase enzymes; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, phosphatidylethanolamine 
N-methyltransferase; RN, diverse cellular substrates; ; S-AdoHcy, S-
adenosylhomocysteine; S-AdoMet, S-adenosylmethionine; SDH, sarcosine 
dehydrogenase; SMS, sphingomyelin synthase; THF, tetrahydrofolate 
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d. Methionine Requirement in TPN 
 Amino acid levels within parenteral solutions have been investigated in recent 
years to determine the optimum concentrations required to increase growth while 
lowering TPN-associated risks in neonates (Brunton et al., 2000). Dietary methionine 
levels have been investigated with and without cysteine supplementation (Shoveller et al., 
2003a; Shoveller et al., 2003b). Cysteine’s ability to spare methionine means that both 
amino acids need to be considered when determining requirements. Oral feeding studies 
in piglets demonstrated that cysteine can spare methionine by up to 70% (Baker et al., 
1969). Studies in TPN also demonstrated this sparing effect. When cysteine is absent 
from parenteral diets, the methionine requirement during TPN was estimated to be 0.29 
g/kg/day, which is approximately 30% less than the requirement for enterally fed piglets 
(Shoveller et al., 2003a). When cysteine was added to the parenteral diet, the methionine 
requirement decreased to 0.18 g/kg/day, which is approximately 70% of the enteral 
requirement in the presence of excess cysteine (Shoveller et al., 2003b), similar to the 
sparing effect of cysteine in oral feeding.  
 Methionine levels in parenteral nutrition solutions are typically investigated in the 
absence of cysteine due to its poor stability in solution because it oxidizes easily to 
cystine, which is insoluble (Vlaardingerbroek et al., 2011). A drawback of providing the 
complete sulfur amino acid requirement (i.e., methionine plus cysteine) in the form of 
methionine is that this approach leads to higher levels of homocysteine in the neonate 
(Shoveller et al., 2004). Moreover, splanchnic tissues play a major role in methionine 
metabolism. The difference between enteral and parenteral methionine requirements is 
attributed to the 30% utilization of sulfur amino acids by the gut (Shoveller et al., 2003a). 
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Overall, when considering sulfur amino acid requirements in parenteral solutions for 
neonates, a balance between methionine and cysteine should be emphasized. When 
methionine is in excess, higher levels of homocysteine is a drawback and is associated 
with TPN cholestasis (Courtney-Martin et al., 2010). 
 
e. Methionine Toxicity 
 Methionine toxicity has been studied due to its link to possible side effects of high 
levels of plasma homocysteine and sulfur toxicity. The possible side effect of high levels 
of homocysteine is usually linked to an increased risk of cardiovascular diseases (Garlick, 
2006). Whether it is an increase in dietary methionine intake that causes this increased 
cardiovascular disease risk has yet to be determined. In 2001, Hanratty and colleagues 
investigated the difference in forearm blood flow response to high oral intakes of 
methionine versus homocysteine. Both treatments resulted in higher concentrations of 
plasma homocysteine and resulted in the same forearm blood flow response (Hanratty et 
al., 2001). This result suggests that it is homocysteine that is responsible for endothelial 
vascular dysfunction. Moreover, it has been demonstrated that significant changes in 
plasma homocysteine concentrations are only seen when methionine intake is five times 
the requirement (Ward et al., 2001). Methionine, being the only sulfur-containing 
essential amino acid, has also been studied to determine if there are possible toxic side 
effects of increased levels of plasma methionine, particularly in infants. Mudd and 
colleagues investigated 10 infants who suffered from hypermethioninemia or 
hyperhomocysteinemia (Mudd et al., 2003). Despite plasma methionine levels rising to a 
high of 6830 µmol/L with normal plasma levels ranging from 10-40 µmol/L, there were 
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no apparent long term clinical side effects of hypermethioninemia associated with these 
infants. So it appears that high dietary methionine becomes toxic via its role in increasing 
plasma homocysteine levels. 
 
1.3 Creatine Additives 
 In addition to its extensive use as a sports supplement and nutraceutical (Wyss & 
Kaddurah-Daouk, 2000), creatine has recently gained interest as a supplement in patients 
suffering from neurodegenerative diseases (Gualano et al., 2012) and in the agriculture 
industry to promote growth (Maddock et al., 2002; Young et al., 2005). Moreover, 
creatine has shown promising effects as a treatment for fatty liver and as a PN additive 
due to its ability to spare methionine and possibly arginine. 
 
1.3.1 Creatine as an Ergogenic Aid 
 Creatine as a sports supplement for athletes has been extensively studied over the 
last number of decades. Despite creatine being synthesized within the body and supplied 
through the diet, typically, through red meat and fish, it is also the most widely used 
sports supplement to increase strength and growth (Gualano et al., 2012). Creatine’s rapid 
conversion to phosphocreatine via creatine kinase explains its effectiveness as a rapid 
source of ATP regeneration during times of high intensity training or exercise. Therefore, 
creatine supplementation may allow for increased phosphocreatine stores in muscle and 
help increase energy and performance, by preventing the depletion of phosphocreatine 
(Wyss & Kaddurah-Daouk, 2000). 
 A recent study demonstrated that combining creatine monohydrate as a 
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supplement with bicarbonate beverages in trained men increased their peak and mean 
power in repeated sprint performance (Barber et al., 2013). Moreover, creatine 
supplementation has been shown to have positive effects in the elderly population in the 
prevention or delay of sarcopenia, which is a loss of muscle tissue as a part of aging. 
Recent findings have shown that creatine supplementation paired with a resistance 
training program significantly decreased the likelihood of sarcopenic changes seen in 
older adults (Devries & Phillips, 2014). The positive effects seen with creatine 
supplementation are still being investigated in a variety of populations. Creatine 
supplementation also has positive effects in patients suffering from neurodegenerative 
diseases such as Alzheimer’s, cancer and rheumatoid arthritis (Gualano et al., 2012). 
Further research is needed in these areas to develop a successful therapy. 
 
1.3.2 Creatine Usage in Neonates and TPN 
 Creatine synthesis is a major consumer of labile methyl groups, consuming 
approximately 70% in the neonate (Brosnan et al., 2009). Depending on the protein 
source, creatine concentrations in infant formula have a broad range from 334 µmol/L in 
cow’s milk formula to approximately 10 µmol/L in soy-based infant formula. Human 
breast milk provides approximately 70 µmol/L of creatine (Edison et al., 2013). 
Variations in concentration between infant formula and physiological levels in human 
milk accounts for some of the variability in findings on the ratio of creatine synthesized 
de novo versus dietary intake. In 2009, Brosnan et al. found that only 25% of the accrued 
creatine in neonatal piglets was supplied by the sow’s milk (Brosnan et al., 2009). 
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Similarly, infants receiving cow-milk based infant formula consumed approximately 35% 
of their creatine via diet (Edison et al., 2013). These findings demonstrate the importance 
of creatine biosynthesis during the neonatal phase which includes very high rates of 
transmethylation and protein turnover.  
 The large percent of labile methyl groups consumed for creatine synthesis during 
the neonatal period places a burden on available methionine for other transmethylation 
reactions. During times of intestinal distress or illness, infants are placed on TPN, which 
is devoid of creatine (Dinesh et al., 2017). This raises the question of whether a larger 
demand is placed on labile methyl groups for de novo synthesis.  
 
1.4 Protein Synthesis in Neonatal Piglets 
 Methionine and arginine are essential amino acids in the neonatal piglet for 
protein synthesis and other non-protein pathways (Brosnan et al., 2009). Because of the 
very rapid protein turnover rates in piglets, supplying adequate amounts of arginine and 
methionine is essential for adequate growth. Moreover, these amino acids are required for 
the rapidly expanding pools of non-protein products. Approximately 70% of creatine is 
synthesized de novo in piglets (Brosnan et al., 2009), so receiving adequate amounts of 
dietary methionine must also accommodate creatine synthesis. Furthermore, increasing 
the demand for one transmethylation product can potentially limit methionine availability 
for protein synthesis and/or other transmethylation products (McBreairty & Bertolo, 
2016).  
 On the other hand, arginine is equally important for optimizing the rate of protein 
synthesis in the neonatal piglet given it is essential in neonates. Arginine’s essentiality is 
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even more pronounced during TPN feeding due to decreased endogenous synthesis by the 
atrophied gut (Bertolo et al., 2000). Because arginine is also required for GAA and 
creatine synthesis, which is very high in neonates, providing adequate dietary arginine 
must also consider the creatine content of the diet, especially during TPN feeding. 
 
1.5 Creatine Transport & Excretion 
 The  bioavailability of dietary creatine has been estimated at approximately 80% 
in adults (MacNeil et al., 2005), whereas in the neonatal animal it has been shown that the 
bioavailability of dietary creatine is likely even higher (Brosnan et al., 2009).   
 Creatine is primarily synthesized in the kidney and liver where AGAT and GAMT 
activity are highly expressed, respectively, as described above. A majority of the body’s 
creatine is synthesized in the liver and exported via Na+ -dependent transporters. These 
Na+ -dependent transporter are members of the “neurotransmitter” transmitter family, 
similar to GABA and taurine transporters (Wyss & Kaddurah-Daouk, 2000). Expression 
of creatine transporters is highest in kidney, heart and skeletal muscle, while lower in 
brain, small and large intestine. Creatine is transported into the skeletal muscle by a 
sodium and chloride dependent transporter (SLC6A8) (Brosnan & Brosnan, 2007). Major 
consumers of creatine include high energy demand tissues such as skeletal and cardiac 
muscle, brain, spermatozoa and retina (Wyss & Kaddurah-Daouk, 2000). However, more 
than 90% of the body’s creatine and phosphocreatine is present in the muscle (Brosnan & 
Brosnan, 2007). 
 Creatine and phosphocreatine are spontaneously converted to creatinine in a non-
enzymatic chemical reaction, which is excreted in the urine Approximately, 1.5-2% of 
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creatine is excreted as creatinine per day (Brosnan & Brosnan, 2016). Therefore, this loss 
must be replaced by either the diet or de novo synthesis. 
 
1.6 Neonatal Piglets as a Model for Pre-Term Infants 
 The neonatal piglet has been a research model for the pre-term infant for many 
years because of the piglet’s similar digestive anatomy and physiology (Miller & Ullrey, 
1987). Moreover, the piglet’s large size (compared to rodents) and accelerated growth are 
very beneficial to research metabolic effects of diet and allow for differences to be 
detected in a shorter period of time (Miller & Ullrey, 1987). Research involving neonatal 
amino acid metabolism is well established in the piglet. The neonatal piglet has very 
similar amino acid requirements to that of an infant (Wykes et al., 1993) and piglet amino 
acid requirement estimates have been shown to be transferrable to the human infant after 
adjusting for the accelerated growth rate of the piglet (Chapman et al., 2009). This study 
involves methionine and arginine metabolism in the neonate, which requires knowledge 
of the methionine and arginine requirements in the piglet. Shoveller and colleagues have 
established the methionine requirement in both parenterally and enterally fed piglets with 
and without excess cysteine (Shoveller et al., 2003a; Shoveller et al., 2003b). Moreover, 
Bertolo and colleagues have estimated the adequate arginine requirement for muscle 
protein synthesis in the orally (Bertolo et al., 2003) and parenterally fed piglet (Brunton et 
al., 2003). Therefore, piglets are a well-established model for clinically relevant research 
applicable to the human neonate. 
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1.7 Rationale, Hypothesis & Objectives 
 Creatine synthesis requires three amino acids, arginine, methionine and glycine 
(Brosnan et al., 2009). Creatine synthesis consumes large amounts of methionine (via 
labile methyl groups), while also consuming arginine. Approximately 70% of creatine 
accretion is synthesized de novo, which consumes the equivalent of 35% of dietary 
methionine and 20% of dietary arginine in the suckling piglet. Methionine and arginine 
are considered essential and conditionally essential, respectively, in the neonate (Dinesh 
et al., 2014; J. Finkelstein et al., 1988). Moreover, during times of gut atrophy as in TPN, 
arginine synthesis is even lower which requires more dietary arginine for protein 
synthesis and growth (Brunton et al., 1999). It has been proposed that creatine 
supplementation may in fact spare arginine and glycine for growth (Hegsted et al., 1941), 
but only when arginine is limited (Wietlake et al., 1954). During times of limited 
methionine intake our group has demonstrated that creatine synthesis is more sensitive to 
methionine and labile methyl group availability than other transmethylation pathways 
(McBreairty et al., 2013). Commercial TPN solutions are devoid of creatine and so 
arginine and methionine requirements must consider synthesis of 100% of creatine needs. 
On the other hand, supplementation of TPN with creatine during marginal supply of 
arginine and methionine may spare both amino acids making them more available for 
growth and protein synthesis. 
 GAA supplementation is effective at increasing creatine stores (Almquist et al., 
1941; McBreairty & Bertolo, 2016), although the methylation of GAA to creatine is not 
feedback regulated, so GAA supplementation in excess may increase the burden on 
methyl groups and methionine (Bertolo & McBreairty, 2013). On the other hand, 
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supplementation with GAA may spare arginine for growth and protein synthesis, as seen 
in broiler chicks fed an arginine deficient diet (Dilger et al., 2013). Therefore, during 
TPN, supplementation with GAA may be effective at increasing creatine muscle stores 
while also sparing arginine for protein synthesis, but only if extra methyl groups and 
methionine are provided. 
 We hypothesized that during TPN feeding, dietary creatine and GAA 
supplementation will spare methionine and arginine for protein synthesis and 
transmethylation reactions in Yucatan miniature piglets. 
 
Objectives: 
01. To quantify the partitioning of methyl groups among transmethylation reactions, 
including creatine and PC synthesis and DNA methylation. 
02. To quantify the sparing effect of creatine and GAA on methionine and/or arginine 
availability for growth, nitrogen retention and protein synthesis. 
03. To determine if supplemental methionine is specifically required to facilitate GAA 
methylation to creatine with supplemental GAA. 
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2. Materials and Methods 
2.1 Animals and Surgical Procedures 
 Our hypothesis was tested in the Yucatan miniature piglet model. All animal 
procedures were reviewed and approved by the Institutional Animal Care Committee at 
Memorial University of Newfoundland and conformed to the guidelines of the Canadian 
Council on Animal Care.	 Thirty-one, 6 – 10 day old piglets were obtained from a 
breeding colony at Memorial University of Newfoundland (St. John’s, NL, Canada). A 
sample size of six per group was calculated with significance level of 0.05 and power of 
0.80 to detect a 10% difference using previous variance estimates from data for 
transmethylation partitioning in piglets; however, our Base + GAA treatment group had a 
sample size of seven, as one of our first piglets in this group showed signs of sickness. 
Our experiment used a randomized complete block (by litter) design obtaining five piglets 
from each litter to maintain blocking. However, six piglets were obtained for the last 
block to replace the sick piglet in the first block; therefore, two piglets were placed in the 
Base + GAA treatment group (n=7). However, all data were included in analyses for 
piglets in Base + GAA (n=7), unless otherwise stated. 
 On the morning of surgery (Day 0) piglets were transported from the breeding 
colony by Animal Care Services to the surgical room located in the Biotechnology 
building at Memorial University of Newfoundland (St. John’s, NL, Canada). Upon 
arrival, piglets were weighed and received an intramuscular injection of Ketamine 
hydrochloride (Bimeda Canada, Cambridge, ON, Canada) and Acepromazine 
(Vetoquinol. QC, Canada) mixture at 22 mg/kg of body weight and 0.5 mg/kg of body 
weight, respectively. Afterwards, anesthesia was maintained by 1.5% Isoflurane (Abbott 
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Laboratories Inc., Canada) mixed with oxygen (1.5 L/minute). A rectal thermometer was 
inserted for monitoring of piglet’s body temperature. Heart rate and oxygen saturation 
were monitored using a pulse oximeter attached to the piglet’s ear. Piglet cleaning before 
surgery consisted of a three-step process: first, piglets were scrubbed and washed with 
Prepodyne solution, second, piglets were washed with 70% Isopropanol (Fisher 
Scientific, Ottawa, ON, Canada) and lastly, piglets received a final wash of Prepodyne 
solution prior to surgery. All surgical tools, gowns and drapes used in the surgical 
procedures were sterilized using an autoclave sterilizer and 45-minute sterilizing dry 
cycle.  
 Prior to surgery, piglets received a dose of Buprenorphine analgesic (Temgesic, 
Reckitt Benckiser Healthcare, UK) at 0.03 mg/kg of body weight. This analgesic was 
repeated 12 h post-surgery and anytime piglets demonstrated signs of pain at 0.015 mg/kg 
of body weight. For surgery, each piglet was implanted with two venous catheters: a 
jugular catheter for administration of diet for 7 d of TPN and a femoral catheter for blood 
sampling. A small paramedian incision was made and a silastic catheter was inserted into 
the external jugular vein and advanced to the cranial vena cava. A second incision was 
made and a silastic catheter was implanted into the left femoral vein and advanced to the 
caudal vena cava. Incisions were closed and piglets received an IV injection of 0.5 mL of 
antibiotic Borgal (Trimethoprim 40 mg/mL and sulfadoxine 200 mg/mL; Intervet Canada 
Ltd, Canada) diluted in 10 mL of saline to prevent the development of infection. Heart 
rate, oxygen levels, body temperature and respiration rate were all monitored and 
recorded in fifteen-minute intervals throughout the surgical procedure. 
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 Post-surgery, piglets were transported to a piglet housing area and placed in 
individual cages using a jacket and tether system. This system allowed the piglets to free 
roam while ensuring the safety of the implanted catheters. The piglet housing area was 
programmed on a 12-hour light and dark cycle. 
 
2.2 Experimental Design and Diet 
 All diets, trace minerals and vitamins used in our study were based on 
commercially available diets for infants (Vaminolact; Fresenius Kabi, Germany) with 
slight modifications made for neonatal piglets (Wykes et al., 1993). Complete elemental 
diets (Table 2.1) were prepared in the laboratory using free crystalline L-amino acids 
(Ajinomoto, Japan; Evonik Industries AG, Hanau-Wolfgang, Germany; Sigma-Aldrich, 
Oakville, Canada). Amino acids were individually weighed and placed in a large beaker 
to be thoroughly mixed. Two 4 L beakers with 1.5 L of pyrogen free water were placed 
on heaters with stirrer bars and heated to 50 - 70oC. Amino acids were then added equally 
to each beaker and dissolved under nitrogen gas. After amino acids were dissolved, D-
glucose (Sigma-Aldrich, Oakville, Canada) was weighed and placed equally into each 
beaker and dissolved. Minerals (Sigma-Aldrich, Oakville, Canada) were weighed and 
dissolved in individual beakers and then added to the amino acid mixtures. A large carboy 
for mixing of diet was placed on a scale to determine final weight of the diet, and amino 
acid mixtures were combined. Diet was then filtered through an AcroPakTM 200 SuporR 
Membrane filter (Pall Corporation, Switzerland) using a mechanical pump (EMD 
Millipore, Darmstadt, Germany) and placed into empty sterile bags (Baxter Corporation, 
Mississauga, ON, Canada) using a 20G 1-inch needle (BD – Canada, Mississauga, ON, 
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Canada) in a laminar flow hood. Each bag was individually weighed to ensure 750 mL 
(795 g) of diet was added and stored at 4oC in a dark environment until ready to be used.  
 Piglets received TPN for 7 d via the implanted jugular catheter by a pressure-
sensitive TPN pump (Baxter FloGard 6301, InfuSystem Inc., USA). Diet was pumped at 
a target rate of 13.5 mL/kg of body weight. Post-surgery (day 0), piglets received 50% of 
target rate. On day 1, the rate was increased to 75% for 12 h, then increased to 100% of 
target rate on the evening of Day 1 until end of study. 
 
2.2.1 Dietary Treatment Groups 
 All piglets received the same complete elemental diet (Adaptation Diet), from Day 
0 – Day 2 to ensure recovery from surgery. To test our hypotheses, on the morning of 
Day 3 piglets were randomized to one of five experimental dietary treatments (Table 2.1). 
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Table 2.1: Amino Acid Profiles of Complete Elemental and Treatment Diets 
 Adaptation 
Diet 
Base Base 
+ 
GAA 
Base + 
Creatine 
Adequate 
Arg & 
Met 
Adequate 
Met + 
GAA 
 g/L g/L g/L g/L g/L g/L 
Alanine 5.89 9.51 8.72 8.73 0.00 7.85 
Arginine 3.65 2.02 2.02 2.02 6.62 2.02 
Aspartate 3.32 3.47 3.47 3.47 2.31 3.47 
Cysteine 0.76 0.83 0.83 0.83 0.83 0.83 
Glutamate 5.72 6.00 6.00 6.00 6.00 6.00 
Glycine 1.47 1.31 1.31 1.31 1.31 1.31 
Histidine 1.69 1.76 1.76 1.76 1.76 1.76 
Isoleucine 2.51 2.64 2.64 2.64 2.64 2.64 
Leucine 5.67 5.94 5.94 5.94 5.94 5.94 
Lysine-HCL 5.58 4.73 4.73 4.73 4.73 4.73 
Methionine 1.04 0.368 0.368 0.368 1.84 1.84 
Phenylalanine  3.00 2.24 2.24 2.24 2.24 2.24 
Proline 4.52 4.73 4.73 4.73 4.73 4.73 
Serine 3.11 3.19 3.19 3.19 3.19 3.19 
Taurine 0.27 0.28 0.28 0.28 0.28 0.28 
Tryptophan 1.14 1.21 1.21 1.21 1.21 1.21 
Tyrosine 0.44 0.43 0.43 0.43 0.43 0.43 
Threonine 2.23 3.03 3.03 3.03 3.03 3.03 
Valine 2.89 3.03 3.03 3.03 3.03 3.03 
GT* 0.00 1.42 1.42 1.42 1.42 1.42 
Creatine (CMH**) 0.00 0.00 0.00 0.43 0.00 0.00 
GAA 0.00 0.00 0.34 0.00 0.00 0.34 
 
Dietary rate of amino acid infusion for piglets was set at 272 mL/kg/d. Diets were 
isonitrogenous by adjusting the concentrations of amino acids, alanine and aspartate. 
*Glycine-Tyrosine dipeptide 
**Creatine Monohydrate 
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Base Diet (Low Arginine & Low Methionine): Feeding a low arginine and low 
methionine diet as TPN allowed for increases in protein synthesis to be detectable (i.e.: by 
sparing either amino acid). Therefore, the Base Diet treatment served as a negative 
control. 
Base + GAA (Low Arginine & Low Methionine plus GAA): Supplementing GAA in 
low arginine and low methionine in TPN tested whether GAA could spare arginine from 
creatine synthesis to be utilized for other uses.  
Base + Creatine (Low Arginine & Low Methionine plus Creatine): Supplementing 
creatine in low arginine and low methionine TPN tested whether creatine could spare 
both arginine and/or methionine from creatine synthesis to be utilized in other 
transmethylation reactions or be used for protein synthesis. 
Adequate Arg & Met (Adequate Arginine & Adequate Methionine): Feeding 
adequate amounts of arginine and methionine in TPN served as a positive control and 
tested whether creatine synthesis is maximized when precursor amino acids are 
adequately fed. In order to accommodate all products of these amino acids, approximately 
150% of estimated piglet requirements were fed. 
Adequate Met + GAA (Low Arginine & Adequate Methionine plus GAA): 
Supplementing GAA in low arginine and adequate methionine in TPN tested whether 
GAA can spare arginine for other uses, while ensuring there is enough methionine 
available for methylation of GAA for creatine synthesis. 
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2.2.2 Trace Mineral Inclusion 
 Trace mineral mixture (Appendix II) was prepared in the laboratory and provided 
at least 120% of NRC requirements for piglets (National Research Council, 1998). 
Individual trace minerals were weighted and placed into a 1 L beaker with 800 mL of 
pyrogen free water. Minerals were stirred and dissolved, then pyrogen free water was 
added to give a total volume of 1 L. Trace mineral mixture was then filtered using a 25 
mm polytetrafluoroethylene (PTFE) 0.45 µm syringe filter (Canadian Life Science, 
Peterborough, ON, Canada) with a 60 cc syringe and a 20G ½ inch needle into an empty 
sterile bag. The mixture was then stored at 4oC until needed. Prior to the administration of 
diet, 3 mL of trace mineral mixture was added using a 5 cc syringe and 20G ½ inch 
needle to the 750 mL amino acid mixture. After this, 1 mL of iron dextran (Ventoquinol 
Canada Inc., Canada) solution was added to the 750 mL amino acid mixture, which 
provides 2 mg of iron per kg of body weight. 
 
2.2.3 Vitamin and Lipid Inclusion 
 Vitamin/K12 mixture (Appendix III) supplied by Baxter Pediatric Multivitamin 
for Infusion (Multi-12/K1 Pediatric multivitamins, Baxter Corporation, Mississauga, ON, 
Canada) provided at least 120% of NRC requirements for piglets in 3 mL (Wykes et al., 
1993). Prior to the administration of diet, 1 mL of Vial 2 was mixed with 4 mL of Vial 1. 
After this mixture was prepared, 3 mL of the vitamin mixture was added to the 750 mL 
amino acid mixture. IV dietary lipid (Appendix IV) was supplied by Baxter Intralipid 
20% (20% Intralipid, Baxter Corporation, Mississauga, ON, Canada)
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provided at 1.1 MJ metabolizable energy/kg/d and lipid and carbohydrate each provided 
50% of the non-protein energy (Wykes et al., 1993). Intralipid was added to the IV diet 
bags immediately prior to the administration of diet; 145 mL of the 20% Intralipid was 
added to 750 mL of diet using a 60 cc syringe and 18G 1 inch needle. 
 
2.3 Isotope Infusion and Necropsy 
 On the morning of day 6, a stable isotope infusion study (Appendix V) was 
performed by another graduate student in our laboratory (A. Al-Jaroudi); the data from 
the stable isotope work are part of the M.Sc. thesis of A. Al-Jaroudi. On day 7, piglets 
received a 6-hour primed-continuous isotopic infusion of L-[methyl-3H] methionine 
(American Radiolabeled Chemicals Inc, St. Louis, MO, USA). Prior to the infusion, 
baseline blood samples were taken from the femoral catheter. At time 0, a priming dose 
of 30 µCi/kg of L-[methyl-3H] methionine was administered into the jugular catheter via 
a Y-connector attached to the TPN catheter. Immediately after the priming dose, a 6-hour 
continuous infusion of L-[methyl-3H] methionine at a rate of 30 µCi/kg/h using a syringe 
pump was initiated into the TPN catheter. Every half-hour from time 0, 0.8 mL of blood 
sample was collected from the femoral catheter and placed in PSTTM gel and lithium 
heparin collection tube (BD-Canada, Mississauga, ON, Canada). Collection tubes were 
centrifuged at 5,000 RPM for 5 min to separate plasma. Plasma supernatant was collected 
and pipetted into 2 mL microcentrifuge tubes (Fisher Scientific, Ottawa, ON, Canada), 
and immediately placed at -80oC for further analyses.  
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 At the end of the 6-hour infusion, piglets were anesthetized via 1.5% isoflurane 
mixed with oxygen (1.5 mL/min) by mask. A midline incision was made and the 
abdomen was exposed. The pancreas, liver and kidney were quickly removed, weighed 
and freeze-clamped in liquid nitrogen. Heart, muscle (bicep femoris), brain, and gut 
samples were then removed, weighed, freeze-clamped in liquid nitrogen and flash frozen. 
Urine from the bladder, and bile from the gallbladder were collected in 2mL 
microcentrifuge tubes and flash frozen in liquid nitrogen. A 30-centimeter section of 
proximal jejunum was removed from the piglet, flushed with ice cold saline, dissected on 
ice, and a mucosal sample was scraped, weighed, freeze-clamped and flash frozen. All 
samples were stored at -80oC until needed for analyses. 
 
2.4 Analytical Procedures 
2.4.1 Plasma and Tissue Amino Acid Concentrations and Specific Radioactivity 
2.4.1.1 Plasma Amino Acids 
 Plasma amino acid samples were analyzed by using reverse-phase high 
performance liquid chromatography (HPLC) following derivatization with 
phenylisothiocyanate (PITC, Edmans Reagent, Thermo Fisher Scientific, USA) 
(Bidlingmeyer et al., 1984). Frozen plasma collected at necropsy (Section 2.5) was 
thawed on ice. Once thawed, 100 µL of plasma supernatant was placed in a 2 mL 
microcentrifuge tube with the addition of 20 µL of 2.5 µmol/mL norleucine standard as 
well as 1 mL of 0.5% trifluoroacetic acid (TFA, Sigma-Aldrich, Oakville, Canada) to 
precipitate plasma proteins. Samples were vortexed and centrifuged at 5000 RPM for 5 
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min. Samples were then poured into 3 mL test tubes, covered, flash frozen with liquid 
nitrogen and placed on a freeze dryer overnight at -50oC. The following day, 50 µL of 
fresh 20:20:60 triethylamine (TEA):methanol:water was added to the test tube. Test tubes 
were then covered, flash frozen with liquid nitrogen and placed on the freeze dryer for 
approximately 1 h at -50oC. After 1 h, samples were removed from the freeze dryer and 
20 µL of derivatizing solution was added to the samples. The derivatizing solution 
contained 10% water, 10% TEA, 70% methanol (Fisher Scientific, Ottawa, ON, Canada), 
10% PITC. Samples were left at room temperature for 35 min to allow the derivatization 
with PITC, then flash frozen in liquid nitrogen and placed on a freeze dryer overnight at -
50oC. The following day, samples were re-suspended in 200 µL of sample diluent [5 mM 
Na2HPO4, (Sigma-Aldrich, Oakville, Canada) titrated to pH 7.4 with 10% H3PO4 and 
10% acetonitrile (Fisher Scientific, Ottawa, ON, Canada)], and centrifuged at 5000 RPM 
for 5 min. Using a glass pipette, avoiding any precipitate, samples were transferred to 0.5 
mL microcentrifuge tubes. 
 A 40 µL sample was injected into a reverse-phase C18 Pico-Tag column (Waters, 
60Å, 4 µm 3.9 X 300 mm, Waters Corporation, Milford, MA, USA) connected to a 
HPLC system. The HPLC system consisted of a Waters 717 plus Auto Sampler Waters 
1525 Binary HPLC pumps, Waters 2487 Dual l absorbance detector and a column heater 
which maintained the column temperature at 46 oC. Mobile buffer phase ‘A’ consisted of 
70 mM sodium acetate (Fisher Scientific, Ottawa, ON, Canada), pH was adjusted to 6.55 
using 6 M hydrochloric acid (HCl, Caledon Laboratory Chemicals, ON, Canada).  and 
2.5% acetonitrile. Mobile buffer phase ‘B’ consisted of 45% acetonitrile, 15% methanol, 
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and 40% water. Both mobile phases were filtered through a nylon, hydrophilic membrane 
(47 mm, 0.45 µm) filter to remove any impurities (Canadian Life Science, Peterborough, 
ON, Canada) and degassed using a vacuum pump as well as a Waters In Line-Degasser 
AF (Waters Corporation, Milford, MA, USA). The derivatized amino acids were detected 
at 254 nm. Peaks were integrated using Empower 3 software (Waters Corporation, 
Milford, MA, USA) and amino acid concentrations were determined by comparing the 
amino acid area to that of the internal standard, norleucine (Sigma-Aldrich, Oakville, 
Canada). A fraction collector (Waters Corporation, Milford, MA, USA) was used to 
collect the eluent that was associated with the methionine peak. A biodegradable liquid 
scintillant (Scintiverse cocktail, Fisher Scientific, Ottawa, ON, Canada) was used to 
determine the radioactivity associated with methionine by liquid scintillation counter 
(PerkinElmer, USA). 
 
2.4.1.2 Tissue Amino Acid Analysis 
a. Tissue Preparation 
 Liver and muscle tissues were completely pulverized using a mortar and pestle 
under liquid nitrogen. Pulverized samples were placed in 20 mL scintillation vials and 
stored at -80oC until further analyses. Tissue samples were homogenized in plastic 
centrifuge tubes with 2% perchloric acid (Fisher Scientific, Ottawa, ON, Canada) at a 
ratio of 1:4 (weight/volume). After homogenizing for approximately 45 s, samples were 
centrifuged at 3000 RPM for 15 min. Supernatant was poured and collected into labeled 
20 mL scintillation vials (Sigma-Aldrich, Oakville, Canada) and the acid-insoluble 
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protein pellet was stored at -20oC for further analysis (Section 2.4.1.2.c). This procedure 
was repeated three times per sample. An internal standard of norleucine was added to the 
supernatant at a concentration of 25 µmol/mL. Supernatant was mixed and stored at -
20oC until further analyses (Section 2.4.1.2.b). 
 
b. Tissue Free Amino Acids 
 Tissue homogenate supernatant was neutralized in a labeled test tube with 2 M 
K2CO3 (Fisher Scientific, Ottawa, ON, Canada). Samples were vortexed and centrifuged 
at 5000 RPM for 3 min. Supernatant was poured off into labeled microcentrifuge tube and 
stored at -20oC after 1 mL of supernatant was transferred to a labeled test tube and 
derivatized as previously described (Section 2.6.1.1). Amino acid concentrations, 
including the radioactivity associated with methionine were quantified using HPLC as 
previously described (Section 2.4.1.1). 
 
c. Tissue Bound Amino Acids 
 Tissue protein pellets were re-suspended in 1 M NaOH (Fisher Scientific, Ottawa, 
ON, Canada) and homogenized with a Teflon pestle. This procedure was repeated 
multiple times until a final volume of 1:9 (weight/volume). Samples were covered, 
inverted to mix and placed in a water bath at 37oC for approximately 1.5 h to solubilize 
the protein. After 100 µL was taken to measure total protein, cold 20% perchloric acid 
(Fisher Scientific, Ottawa, ON, Canada) was added to the samples to re-precipitate 
protein. The protein concentration is needed to calculate absolute synthesis rate (ASR) of 
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protein. Samples were placed on ice for 20 min and centrifuged at 4800 RPM for 15 min. 
The supernatant was discarded and an internal standard of norleucine was added at a 
concentration of 25 µmol/mL. The pellet was disrupted and transferred to a labeled test 
tube with 6 M HCl (10 mL/g of tissue). The protein pellet was then hydrolyzed at 110oC 
for 24 h. Test tubes were removed from the oven and placed in the fume hood to cool 
overnight. Hydrolysates were mixed and placed in pre-weighed flasks and diluted to a 
final volume of 25 mL was reached. Contents of the flask were mixed thoroughly and 
filtered through a 25 mm PTFE 0.45 µm syringe filter (Canadian Life Science, 
Peterborough, ON, Canada) into a 20 mL scintillation vial and stored at -20oC. Samples 
(1 mL) were transferred to plastic centrifuge tubes and placed in a drying oven overnight 
and derivatized, as previously described (Section 2.4.1.1.). Muscle samples were directly 
hydrolyzed with 6 M HCl after the addition of the internal standard, norleucine, to the 
protein pellet. A solubilized sample was not needed since ASR cannot be calculated for 
muscle. The concentrations of methionine and its associated radioactivity were measured 
using HPLC and fraction collecting, as previously described (Section 2.4.1.1). 
 
2.4.2 Analysis of Transmethylation Products 
2.4.2.1 Quantification of Creatine Concentrations and Specific Radioactivity 
 Tissue creatine concentrations and specific radioactivity were quantified using a 
modified method by Lamarre (Lamarre et al., 2010). Approximately 200 mg of frozen 
tissue was weighed into a plastic centrifuge tube and homogenized with 950 µL of 0.5 M 
Tris Buffer at pH 7.4 (Fisher Scientific, Ottawa, ON, Canada).  Samples were transferred 
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to 1.5 mL centrifuge tubes and 50 µL of trifluoroacetic acid was added (Sigma-Aldrich, 
Oakville, Canada). Samples were left on ice for 10 min to precipitate protein. Muscle 
samples required more time to precipitate protein, therefore they were left on ice for 30 
min. Samples were centrifuged at 6000 RPM for 10 min at a temperature of 4oC. 
Supernatant was filtered for solid phase extraction through 40 µm C18 Bond Elut filters 
(Agilent Technologies, CA, USA) into labeled 0.5 mL microcentrifuge tubes (Fisher 
Scientific, Ottawa, ON, Canada). Filters were cleaned between each sample once with 
methanol ((99%) Fisher Scientific, Ottawa, ON, Canada) and twice with HPLC-grade 
water. A standard curve was quantified using a Waters 2487 Dual l absorbance detector 
at 210 nm through a Hypercarb 5µm Carbon 250 column (Waters Corporation, Milford, 
MA, USA). HPLC mobile phase consisted of 0.1% TFA (Sigma-Aldrich, Oakville, 
Canada) and 3% methanol (Fisher Scientific, Ottawa, ON, Canada) in HPLC-grade water 
at an isocratic rate of 1.0 mL/min for 20 min per sample. Creatine peaks were detected 
using EmPower 3 software and a fraction collector was used to the creatine peak. 
Radioactivity associated with creatine was determined as previous described (Section 
2.4.1.1). 
 
2.4.2.2 Quantification of Phosphatidylcholine Concentrations and Specific 
Radioactivity 
 Total lipid was extracted from liver tissue using the Folch method (Folch et al., 
1957). Approximately 300 mg of frozen liver tissue was weighed and transferred to a 
plastic centrifuge tube with the addition of 900 µL of 50 mM NaCl (Fisher Scientific, 
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Ottawa, ON, Canada). Tissue was homogenized for 45 s and transferred to acid-washed 
glass tubes. (Glass tubes were acid-washed in concentrated H2SO4, (Fisher Scientific, 
Ottawa, ON, Canada) for 24 h, then rinsed in running water overnight). A 2:1 
chloroform:methanol (Fisher Scientific, Ottawa, ON, Canada) solution was prepared and 
6 mL was added to each sample and extensively vortexed. Samples were left at 4oC 
overnight. Tissue samples were centrifuge at 3000 RPM for 10 min to allow for 
separation of lipids and aqueous phase. The lipid/chloroform layer was extracted and 
placed in a pre-weighed glass culture tube; the extracted lipids were dried under nitrogen 
gas. Glass culture tubes were weighed to determine the total fat within each sample. 
Extracted lipids were re-suspended by adding 300 µL of 99% isopropanol (Fisher 
Scientific, Ottawa, ON, Canada), vortexed and transferred to 1.5 mL microcentrifuge 
tubes to be stored at -80oC until further analyses. Samples were spotted onto a K6 Silica 
Gel-G60 thin-layer chromatography (TLC) plate (EMD, Millipore Corporation, Billerica, 
MA, USA) in 5 µL increments until a total volume of 20 µL was reached. A 
chloroform:methanol:acetic acid:water (25:15:4:2) mobile phase was prepared and added 
to a mobilization chamber and complete saturation required approximately 1 h. Plates 
were removed when the mobile phase reached the top of the plate and transferred to an 
iodine visualization chamber for the appearance of phosphatidylcholine bands. 
Phosphatidylcholine was scraped using a razor blade and transferred to acid-washed glass 
tubes with the addition of 400 µL of 70% perchloric acid (Fisher Scientific, Ottawa, ON, 
Canada). Samples were placed into a heating oven at 180oC for 2 h until samples became 
clear and removed to sit at room temperature. Samples were centrifuge at 5000 RPM for 2 
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min and 100 µL was transferred to a glass culture tube where it was diluted with 200 µL 
70% perchloric acid (Fisher Scientific, Ottawa, ON, Canada). Total phosphate 
measurement was quantified using a modified method from Bartlett (Bartlett, 1959) and a 
standard phosphate stock solution. Samples and standards were prepared by adding 50 µL 
of 5 % ammonium molybdate (Fisher Scientific, Ottawa, ON, Canada) and 50 µL of 1-
amino-2-naphthol-6-sulphonic acid (ANSA) solution and vortexed. Sample and standard 
volumes were matched by the addition of 500 µL of deionized water to each sample. 
Samples and standards were placed in a water bath at 100oC for 12 min to allow for 
reaction and colour change. Samples were removed, cooled to room temperature and 
absorbance of both samples and standards were quantified at 815 nm using a dual-
absorbance spectrophotometer. After reading the absorbance, 600 µL of the sample was 
removed from the cuvette and placed in a 20 mL scintillation vial. Radioactivity 
associated with phosphatidylcholine was determined as previously described (Section 
2.4.1.1). 
 
2.4.2.3 Quantification of DNA Concentration and Specific Radioactivity 
 Approximately 300 mg of liver tissue was weighted in a plastic centrifuge tube 
and homogenized for 30 s in 4.0 mL of buffer (50 mM Tris, 100 mM EDTA, 100 mM 
NaCl, 1% SDS) (Fisher Scientific, Ottawa, ON, Canada; Sigma-Aldrich, Oakville, 
Canada) and 450 µL of proteinase K (Sigma-Aldrich, Oakville, Canada) solution. Tissue 
homogenates were transferred to 15 mL glass test tubes and placed in the water bath at 
56oC for 12 h overnight. Phenol solutions were prepared by melting 150 g of pure phenol 
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(Sigma-Aldrich, Oakville, Canada) at 56oC for 1 h and then adding an equal amount of 
0.20 M solution of Tris (Fisher Scientific, Ottawa, ON, Canada). Aliquots were placed 
into 50 mL plastic test tubes and stored at -20oC until needed. Tissue samples were 
removed from the water bath and an equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) (Fisher Scientific, Ottawa, ON, Canada) was added to the samples, vortexed 
and centrifuged at 8000 RPM for 10 min until a phenol and aqueous layer formed. 
Aqueous layer was extracted and placed in a new 15 mL test tube. This process was 
repeated once more until no protein inference remains between the phenol and aqueous 
phases. An equal volume of choloroform:isoamyl alcohol ((24:1) Fisher Scientific, 
Ottawa, ON, Canada) was added and centrifuged at 5000 RPM for 15 min to recover the 
aqueous phase and transferred to a new 15 mL test tube. An equal volume of 99% 
isopropanol (Fisher Scientific, Ottawa, ON, Canada) and 1/10 the volume of 1.0 M 
sodium acetate (Sigma-Aldrich, Oakville, Canada) was added and centrifuged at 5000 
RPM for 15 min to precipitate the DNA. The pellet was rinsed twice with 70% ethanol 
(Fisher Scientific, Ottawa, ON, Canada) and once in 95% ethanol. The pellet was 
removed from the 15 mL test tube and transferred to a 1.5 mL microcentrifuge tube to dry 
for approximately 20 min. After the pellet has completely dried, 1.0 mL of TE buffer (10 
mM Tris, 0.1 mM EDTA) (Fisher Scientific, Ottawa, ON, Canada) was added to re-
suspend the DNA in solution. The pellet was then dissolved in a rocking water bath at 
56oC for 20 min, removed and stored at 4oC overnight. The DNA concentration was 
determined using Thermo Scientific Nano Drop 2000 spectrophotometer (Thermo Fisher 
Scientific, Canada) and radioactivity associated with DNA was determined as previously 
described (Section 2.4.1.1). 
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2.4.2.4 Quantification of SAM & SAH Concentrations and Specific Radioactivity 
Associated with SAM 
 Liver tissue SAM and SAH concentrations were quantified using a modified 
method by Ratnam and colleagues (Ratnam et al., 2006). Approximately 200 mg of 
frozen liver tissue were weighed in a plastic centrifuge tube and homogenized for 45 
seconds in 1 mL of ice cold 8% trichloroacetic acid (Fisher Scientific, Ottawa, ON, 
Canada). Homogenized samples were transferred to 1.5 mL microcentrifuge tubes (Fisher 
Scientific, Ottawa, ON, Canada) and centrifuged at 12,000 RPM for 5 min. Supernatant 
was extracted and filter through 13 mm PTFE 0.45 µm syringe filter (Canadian Life 
Science, Peterborough, ON, Canada) into labeled 0.5 mL microcentrifuge tubes (Fisher 
Scientific, Ottawa, ON, Canada). A standard curve was quantified using a Waters 2487 
Dual l absorbance detector at 258 nm through a VYDAC HPLC C18 column (Waters 
Corporation, Milford, MA, USA). Mobile phase ‘A’ consisted of 50 mM NaH2PO4 
(Sigma-Aldrich, Oakville, Canada) and 10 mM heptane sulfonic acid at pH 3.2 (Fisher 
Scientific, Ottawa, ON, Canada) in HPLC-grade water. Mobile phase ‘B’ consisted of 
100% acetonitrile (Fisher Scientific, Ottawa, ON, Canada). Both mobile phases were 
filtered through a 47 mm nylon, hydrophilic 0.45 µm filter to remove any impurities 
(Canadian Life Science, Peterborough, ON, Canada) and degassed using a Waters In 
Line-Degasser AF. 50 µL of sample was injected and buffers infused at a rate of 1.0 
mL/min for 30 min. SAM peaks were detected and a fraction collector ((Waters Fraction 
Collector III) Waters Corporation, Milford, MA, USA) was used to collect the sample 
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that was associated with the SAM peak. Radioactivity associated with SAM was 
determined as previously described (Section 2.4.1.1). 
 
2.4.3 Analysis of Plasma Creatine 
 Plasma creatine concentrations and specific radioactivity was quantified using a 
modified method by Lamarre (Lamarre et al., 2010). Plasma, 50 mM Tris buffer (Fisher 
Scientific, Ottawa, ON, Canada) and 97% TFA (Fisher Scientific, Ottawa, ON, Canada) 
(3:2:0.5) were mixed in a 1.5 mL microcentrifuge tube (Fisher Scientific, Ottawa, ON, 
Canada), vortexed and placed on ice for 10 min. Samples were centrifuged at 6000 RPM 
for 10 min. Creatine concentrations and radioactivity was determined as previously 
described (Section 2.4.2.1). 
 
2.4.4 Hepatic GAMT Activity 
 Liver GAMT activity was quantified using a modified method by Ogawa (Ogawa 
et al., 1983). Fresh liver tissue was manually homogenized, 1:5 (w/v) in a sucrose HEPES 
buffer (0.25 M sucrose, 1 mM EDTA, and 10 mM Hepes) (Sigma-Aldrich, Oakville, 
Canada) and centrifuged at 35,000 RPM at 4oC for 60 min. Supernatant was used to 
determine hepatic GAMT activity. To start, 10 µL of supernatant was combined with 350 
µL of Tris b-mercaptoethanol buffer (100 mM Tris and 20 mM b-mercaptoethanol) 
(Fisher Scientific, Ottawa, ON, Canada; Sigma-Aldrich, Oakville, Canada) and 620 µL of 
deionized water, then 10 µL of SAM solution (4.4 mg of SAM in 500 µL deionized water 
+ 500 µL Tris b-mercaptoethanol buffer) (Fisher Scientific, Ottawa, ON, Canada; Sigma-
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Aldrich, Oakville, Canada) was added and samples were incubated at room temperature 
for 10 min. The reaction took place when 10 µL of GAA solution (23.42 mg GAA in 5 
mL deionized water + 5 mL L Tris b-mercaptoethanol buffer) (Fisher Scientific, Ottawa, 
ON, Canada; Sigma-Aldrich, Oakville, Canada) was added and samples were incubated at 
37oC for 20 min. After 20 min incubation at 37oC, the reaction was stopped when 750 µL 
of 15% trichloroacetic acid was added, vortexed, and placed on ice for 10 min. Then 720 
µL of 1 M Tris buffer was added to neutralize the reaction. Measuring creatine production 
to quantify hepatic GAMT activity was determined by derivatizing 400 µL of supernatant 
as described below (Section 2.4.4.1). 
 
2.4.4.1 Derivatization using Ninhydrin 
 Hepatic GAMT activity was determined using a modified method by Buchberger 
and Ferdig (Buchberger & Ferdig, 2004).  Samples, 1.3 M KOH, and 0.9% Ninhydrin 
(4:3:1.5) were mixed and incubated at room temperature in a dark environment for 15 
min. After incubation, 100 µL of 5% ascorbic acid (Sigma-Aldrich, Oakville, Canada) 
and 5 M phosphoric acid (Fisher Scientific, Ottawa, ON, Canada) were added and 
samples were incubated at 90oC for 30 min. After incubation, samples were cooled to 
room temperature and filtered using a 13 mm PTFE 0.45 µm syringe filter (Canadian Life 
Science, Peterborough, ON, Canada) into a labeled 0.5 mL microcentrifuge tube (Fisher 
Scientific, Ottawa, ON, Canada). Samples (50 µL) were injected on a YMC-Pack Pro 
C18 column (150 X 4.6 mm I.D., 3 µm) (YMC America, Inc., Allentown, PA, USA) and 
creatine was separated using reverse-phase HPLC. Samples were run for 32 min with a 
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flow rate of 1 mL/min. Mobile phase ‘A’ consisted of 50 mM formic acid (Sigma-
Aldrich, Oakville, Canada) and mobile phase ‘B’ consisted of 100% methanol (Fisher 
Scientific, Ottawa, ON, Canada). Samples were detected by a Waters 474 scanning 
fluorescence detector at 470 nm emission and 390 nm excitation (Waters Corporation, 
Milford, MA, USA). A standard curve was used for quantification of creatine peaks and 
peaks were identified using EmPower 3 software (Waters Corporation, Milford, MA, 
USA). 
 
2.5 Calculations 
 Specific radioactivity (SRA) of transmethylated products, methionine and SAM 
were calculated as DPM/nmol. Plateaus were determined by visual inspection and 
verified by a non-significant linear regression of the data set. For all infusions, the mean 
of plasma methionine SRA at plateau was calculated using data collected between 4 and 6 
h of the L-[methyl-3H] methionine infusion. Methionine flux was calculated using the 
following equation: 
Flux (µmol/kg/h) = L-[methyl-3H] Methionine infusion rate (DPM/kg/h)/Mean 
methionine SRA of methionine at plateau (DPM/µmol) 
Fractional Synthesis Rate (FSR) of protein and transmethylation products were calculated 
using the following equation: 
Fractional Synthesis Rate (%/h) = SRA of product / SRA of precursor * 100/time 
SRA of hepatic SAM was used as a SRAprecursor for calculations of FSR of 
transmethylation products, but SRA of the tissue-free methionine was used as SRAprecursor 
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to calculate the FSR of tissue specific protein synthesis. Time refers to the duration of 
labelling in hours; time of L-[methyl-3H] methionine infusion. 
Proportion of the 3H-methyl products remaining in the liver at the end of the study was 
calculated using the following equation: 
% = (DPM of product/g of tissue) / (DPM sum of all measured products/g of tissue)*100 
 
2.6 Statistical Analyses 
 Data on piglets were analyzed using n=6 and n=7 (Base + GAA), unless otherwise 
stated. Data were analyzed by one-way ANOVA with Tukey’s multiple comparisons 
post-hoc test using GraphPad Prism 7 (Graph Pad Software, San Diego, CA, USA). The 
alpha level was set at 0.05. All data were reported as mean ± standard deviation. 
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3. Results 
 The study’s two major outcomes were to measure whole body amino acid and 
protein turnover with the use of stable isotopes (performed by another graduate student; 
Alaa Al-Jaroudi) and tissue-specific transmethylation and protein synthesis (the subject of 
this thesis). The study design and outcomes were similar to previous research completed 
in our laboratory for an intragastric (IG) feeding model.  Based on sample size calculation 
using data from the previous study, we calculated that a sample size of n=6 was sufficient 
for the current study. Due to suspected sickness in one of our piglets in Base + GAA 
treatment group, we added another piglet to this treatment group. This resulted in a 
sample size of n=7 for the Base + GAA treatment group to ensure we had at least 6 
healthy piglets in each treatment group for all outcomes. 
 
3.1 Growth and Weight Analysis of Piglets 
3.1.1 Piglet Weight Gain 
 Piglets receiving Adequate Met + GAA treatment had significantly greater weight 
gain during 5 d of treatment (p < 0.05) compared to piglets receiving Base, Base + GAA 
and Base + CRE diet throughout the 5 days of treatment diets (Figure 3.1). At necropsy 
on Day 7, no differences were found for organ weights across treatment groups (Table 
3.1). 
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Figure 3.1: Effects of Diet on Piglet Weight Gain over 5 d of Treatment 
Bars represent means (± standard deviations). For piglet weight analysis (n=6) for all 
treatment groups. One-way ANOVA followed by Tukey’s multiple comparisons (p < 
0.05) were used to test for differences among diets. Significant differences among groups 
are shown by the different letters above each bar. 
Adeq, Adequate; Arg, Arginine; CRE, Creatine; GAA, Guanidinoacetic acid; Met, 
Methionine 
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Table 3.1: Weight of Piglet Organs after 5 d of Treatment Diet 
Treatment 
 Base Base + 
GAA 
Base + CRE Adequate 
Arg & Met 
Adequate 
Met + GAA 
Piglet Organ 
Liver 46.0±2.5 
 
44.8±3.3 
 
45.1±1.2 
 
40.7±5.4 
 
46.7±7.0 
 
Kidney* 4.3±0.3 4.6±0.9 4.5±0.6 3.9±0.2 4.4±0.4 
Heart 6.6±0.6 6.3±0.4 6.7±0.7 6.3±0.2 6.5±0.4 
Brain 14.6±1.6 
 
14.0±2.7 
 
15.5±3.9 
 
13.7±1.0 
 
14.2±1.7 
 
 
Data represent means ± standard deviations (g/kg of BW). One-way ANOVA followed 
by Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets; 
there were no differences among treatments. 
* Represents the weight of the left kidney. 
Arg, Arginine; CRE, Creatine; GAA, Guanidinoacetic acid; Met, Methionine 
 
3.1.2 72-Hour Urinary Nitrogen Retention 
 Nitrogen retention was completed by another graduate student, but are presented 
here for reference. Urine was collected every 24 h for 3 consecutive days. As shown 
below in Figure 3.2, piglets receiving Adequate Met + GAA had significantly greater 72-
hour nitrogen retention (%) compared to piglets receiving a treatment diet of Base + GAA 
(p < 0.05). 
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Figure 3.2: 72-Hour Percent Nitrogen (N) Retention Across all Treatment Groups 
Bars represent means ± standard deviations for % N retention. For % N retention analysis 
(n=5) for Base + GAA and Met+GAA. One-way ANOVA followed by Tukey’s multiple 
comparisons (p < 0.05) were used to test for differences among diets. Significant 
differences among groups are shown by the different letters above each bar. 
Adeq, Adequate; Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine; N, 
Nitrogen 
 
3.2 Plasma Metabolite Analysis 
3.2.1 Plasma Amino Acid and Creatine Concentrations 
 Piglets receiving Adequate Arg & Met, and Adequate Met + GAA had 
significantly higher (p < 0.05) plasma methionine concentrations than all other treatment 
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groups, reflecting dietary intake. In the Adequate Arg & Met group, plasma arginine and 
ornithine concentrations were found to be significantly greater (p < 0.05) but plasma 
glutamine and alanine concentrations were found to be significantly lower (p < 0.05) 
compared to all other treatments (Table 3.2). Piglets receiving supplemental creatine 
(CRE) had higher plasma concentrations of tyrosine (p < 0.05) compared to piglets fed 
Base + GAA, Adequate Arg & Met, and Adequate Met + GAA diets. Plasma glycine was 
significantly higher (p < 0.05) in piglets receiving Adequate Arg & Met compared to 
piglets receiving Base + GAA. Piglets supplemented with creatine had significantly 
greater (p < 0.05) plasma concentrations of serine compared to those receiving Adequate 
Met + GAA. A diet high in arginine and methionine also led to a lower plasma creatine 
concentration (p < 0.05) compared to all other treatments. Unexpectedly, piglets receiving 
supplemental creatine did not show elevated levels of plasma creatine, compared to all 
other treatments. 
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Table 3.2: Plasma Metabolite Concentrations after 5 d of Treatment Diet 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Non-Essential Amino Acids 
Alanine 685 ± 112a 619 ± 94a 665 ± 59a 326 ± 146b 710 ± 37a 
Hydroxyproline 56 ± 5 48 ± 7 51 ± 4 70 ± 29 60 ± 4 
Proline 613 ±143 580 ± 63 632 ± 68 674 ± 270 633 ± 42 
Tyrosine 192 ± 43ab 129 ± 24b 234 ± 46a 158 ± 63b 146 ± 32b 
Glutamine 369 ± 45a 294 ± 77a 361 ± 55a 155 ± 63b 325 ± 92a 
Glutamate 159 ± 21 148 ± 35 142 ± 15 97 ± 38 125 ± 21 
Citrulline 114 ± 23ad 116 ± 18a 123 ± 23ab 79 ± 37c 83 ± 20cd 
Ornithine 43 ± 11ab 45 ± 10ab 57 ± 12b 168 ± 67c 45 ± 6a 
Essential Amino Acids 
Arginine 105 ± 14a 100 ± 14a 122 ± 25a 381 ± 146b 86 ± 7a 
Histidine 141± 23 119 ± 11 137 ± 59 108 ± 46 105 ±23 
Isoleucine 217 ± 23 210 ± 45 202 ± 43 175 ± 67 181 ±18 
Leucine 416 ± 76 388 ± 90 424 ± 80 405 ± 160 429 ± 45 
Lysine 437 ± 132 415 ± 86 514 ± 131 471 ± 162 399 ± 58 
Phenylalanine 192 ± 26 179 ± 21 178 ± 13 209 ± 80 197 ± 55 
Threonine 345 ± 73 330 ± 43 356 ± 52 361 ± 143 338 ± 40 
Tryptophan 132 ± 18 115 ± 18 120 ± 23 130 ± 51 106 ± 14 
Valine 438 ± 38 397 ± 70 417 ± 91 380 ± 146 368 ± 48 
Sulfur Amino Acid Metabolites 
Glycine 1037 ± 113ab 924 ± 88a 1122 ± 145b 1134 ± 438b 1078 ± 98ab 
Methionine 66 ± 15a 72 ± 22a 81 ± 18a 233 ± 99b 220 ± 43b 
Serine 684 ± 128a 525 ± 94ab 712 ± 76a 512 ± 204b 518 ± 76b 
Taurine 217 ± 39 185 ± 33 192 ± 37 192 ± 76 214 ± 19 
Other Metabolites 
Creatine 300 ± 141a 251 ± 59a 256 ± 35a 74 ± 46b 139 ± 87a 
 
Data represent means ± standard deviations in µmol/L. One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Means within rows not sharing a superscript letter were different.  
Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
	 60	
3.2.2 Plasma SRA of Creatine 
 Plasma SRA of creatine was significantly greater (p < 0.05) in piglets 
supplemented with adequate methionine and arginine compared to piglets receiving all 
low methionine diets (Figure 3.3). Moreover, piglets supplemented with GAA in the 
presence of adequate methionine had higher (p < 0.05) plasma SRA of creatine, but only 
compared to piglets supplemented with creatine. 
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Figure 3.3: Plasma SRA of Creatine After 5 d of Treatment Diet 
Bars represent means ± standard deviations in DPM/nmol. One-way ANOVA followed 
by Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Significant differences among groups are shown by the different letters above each bar. 
Adeq, Adequate; Arg, Arginine; DPM, Disintegrations per minute; GAA, 
Guanidinoacetic acid; Met, Methionine 
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3.3 Hepatic Free Amino Acids Concentrations 
 Analysis of hepatic free amino acids revealed that hepatic concentration (μmol/g 
of tissue) of methionine was significantly greater in piglets receiving Adequate Arg & 
Met and Adequate Met + GAA compared to all other treatments (Table 3.3) (p < 0.05). 
Hepatic free arginine concentrations were significantly greater in piglets receiving 
Adequate Arg & Met, but only compared to piglets receiving a treatment diet of Base + 
GAA diet (p < 0.05). Moreover, hepatic phenylalanine and ornithine concentrations were 
significantly greater in piglets receiving Adequate Arg & Met diet compared to piglets 
receiving a Base, Base + GAA and Base + Creatine diet (p < 0.05). Piglets receiving 
Adequate Met + GAA had significantly lower concentrations of ornithine, compared to 
all other treatments, while hepatic proline concentrations were shown to be significantly 
greater compared to piglets receiving a diet of Base + GAA diet (p < 0.05). 
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Table 3.3: Hepatic Free Amino Acid Concentrations after 5 d of Treatment Diet 
Treatment 
 Base Base + GAA Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Non-Essential Amino Acids 
Alanine 1056 ± 398 1516 ± 844 1437 ± 751 1267 ± 249 1728 ± 578 
Aspartate 710 ± 153 712 ± 97 552 ± 337 693 ± 67 849 ± 105 
Hydroxyproline 1773 ± 119a 1662 ± 186a 1316 ± 325ab 1043 ± 318b 1234 ± 219b 
Proline 575 ± 134ab 914 ± 299a 995 ± 205ab 1107 ± 291ab 1484 ± 704b 
Tyrosine 162 ± 57 191 ± 166 218 ± 71 165 ± 29 175 ± 67 
Glutamine 1631 ± 346a 1658 ± 240a 1739 ± 291a 873 ± 153b 1550 ± 207a 
Glutamate 1253 ± 98 1232 ± 165 953 ± 419 1177 ± 84 1246 ± 175 
Citrulline 1499 ± 688 1233 ± 441 1072 ± 624 667 ± 434 1027 ± 620 
Ornithine 637 ± 142a 575 ± 129a 624 ± 101a 860 ± 132b 282 ± 103c 
Essential Amino Acids 
Arginine 126 ± 81ab 71 ± 18a 98 ± 40ab 171 ± 49b 148 ± 52ab 
Histidine 189 ± 32 232 ± 24 183 ± 44 376 ± 250 411 ± 200 
Isoleucine 228 ± 25 230 ± 29 229 ± 23 194 ± 25 195 ± 18 
Leucine 449 ± 43 462 ± 29 466 ± 45 464 ± 59 471 ± 57 
Lysine 1491 ± 611 1351 ± 497 1373 ± 550 733 ± 78 723 ± 180 
Phenylalanine 150 ± 18a 158 ± 18a 164 ± 33a 224 ± 38b 182 ± 30ab 
Threonine 1099 ± 634 595 ± 426 782 ± 225 537 ± 190 726 ± 675 
Valine 403 ± 47 416 ± 64 437 ± 99 375 ± 101 397 ± 100 
Sulfur Amino Acid Metabolites 
Glycine 3734 ± 413 3449 ± 203 4113 ± 932 3765 ± 326 3606 ± 350 
Methionine 55 ± 14a 49 ± 9a 40 ± 15a 119 ± 24b 126 ± 29b 
Serine 3349 ± 323a 2724 ± 724ab 3399 ± 409a 2301 ± 251b 2131 ± 277b 
Taurine 3753 ± 309 4376 ± 1362 4747 ± 1671 5955 ± 1904 5957 ± 1208 
 
Data represent means ± standard deviations in nmol/g tissue. One-way ANOVA followed 
by Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Means within a row not sharing a superscript letter were different.  
Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
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3.4 Hepatic Metabolite Concentrations 
 Other hepatic metabolite concentrations were analyzed (Table 3.4). There were no 
significant differences in hepatic creatine or phosphatidylcholine concentrations (p < 
0.05) among diets. However, hepatic SAM concentrations were significantly greater in 
piglets receiving a diet Adequate Arg & Met and Adequate Met + GAA diets compared to 
all other treatments (p < 0.05). Hepatic TG were greater in piglets fed Adequate Met + 
GAA compared to piglets fed a Base diet supplemented with creatine (p < 0.05). 
 
Table 3.4: Hepatic Metabolite Concentrations after 5 d of Treatment Diet 
Treatment 
 Base Base + GAA Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Hepatic Metabolites 
Creatine 1.5 ± 0.8 1.6 ± 0.4 1.2 ± 0.2 0.9 ± 0.2 2.2 ± 1.66 
PC 26.8 ± 4.1 30.0 ± 6.7 27.8 ± 8.6 30.3 ± 4.8 29.8 ± 6.5 
DNA 2.8 ± 0.6 2.9 ± 0.4 2.8 ± 0.4 2.8 ± 1.9 2.3 ± 0.3 
SAM 0.05 ± 0.03b 0.06 ± 0.03b 0.06 ± 0.05b 0.5 ± 0.06a 0.4 ± 0.2b 
SAH 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 
TG 0.21 ± 0.06ab 0.18 ± 0.04ab 0.12 ± 0.04a 0.17 ± 0.06ab 0.24 ± 0.10b 
Cholesterol 1.0 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 
SAM:SAH 2.2 ± 1.0a 1.8 ± 0.9a 2.4 ± 1.6a 13.3 ± 2.8b 11.5 ± 1.9b 
 
Data represent means ± standard deviations in µmol/g of tissue for all metabolites except 
TG and cholesterol (mg/g) and DNA (103 ng/µL). One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Means not sharing a superscript letter within a row were different.  
DNA, deoxyribonucleic acid; GAA, Guanidinoacetic acid; PC, Phosphatidylcholine; 
SAM, S-adenosyl methionine; SAH, S-adenosyl homocysteine; TG, triglyceride 
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3.5 Muscle Free Amino Acids & Metabolite Concentrations 
 Data for muscle metabolites (Table 3.5) were not different among treatment 
groups.  
 
Table 3.5: Muscle Free Amino Acid & Metabolite Concentrations after 5 d of 
Treatment Diet 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Muscle Metabolites 
Methionine 0.4 ± 0.2 0.3 ± 0.2 0.1 ± 0.04 0.4 ± 0.3 0.4 ± 0.2 
Glycine 3.1 ± 0.6 3.1 ± 0.48 3.5 ± 0.41 3.8 ± 0.56 3.7 ± 1.2 
Taurine 4.6 ± 1.0 4.2 ± 1.3 4.9 ± 1.2 5.5 ± 0.8 4.4 ± 1.0 
Creatine 18.1 ± 4.4 15.4 ± 5.9 20.5 ± 1.9 20.5 ± 2.7 20.2 ± 3.9 
	
Data represent means ± standard deviations in µmol/g of tissue. One-way ANOVA 
followed by Tukey’s multiple comparisons (p < 0.05) were used to test for differences 
among diets; data were not different. 
 Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
 
3.6 Methionine Kinetics 
3.6.1 Plasma Methionine Kinetics 
3.6.1.1 Plasma Methionine SRA 
Plasma methionine SRA at steady state was determined using the plasma SRA of 
methionine for and last five plasma samples from the 6-hour L-[methyl-3H] methionine 
infusion. Steady state plasma methionine SRA (DPM/µmol) was significantly greater (p < 
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0.05) in piglets receiving adequate methionine compared to all other treatments (Figure 
3.4). 
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Figure 3.4: Steady State Plasma Methionine SRA on Day 7 
Bars represent means ± standard deviations in DPM/nmol. One-way ANOVA followed 
by Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Significant differences among groups are shown by the different letters above each 
column.  
Adeq, Adequate; Arg, Arginine; DPM, disintegrations per minute; GAA, Guanidinoacetic 
acid; Met, Methionine 
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3.6.1.2 Plasma Methionine Flux 
 Plasma L-[methyl-3H]-methionine flux was significantly lower in piglets receiving 
adequate methionine diets compared to low methionine diets (Figure 3.5). 
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Figure 3.5: Plasma L-[Methyl-3H]-Methionine Flux on Day 7 Infusion 
Bars represent means ± standard deviations in µmol/kg/h. One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Significant differences between groups are shown by the different letters above each 
column. 
Adeq, Adequate; Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
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3.6.2 Hepatic Methionine Kinetics 
3.6.2.1 Hepatic SRA of Methionine and Transmethylated Products 
 Hepatic SRA of transmethylated products was analyzed using the L-[methyl-3H] 
methionine tracer (Table 3.6). Hepatic free methionine SRA was significantly greater (p < 
0.05) in piglets receiving Adequate Arg & Met and Adequate Met + GAA diet compared 
to all other treatments. Hepatic protein-bound methionine SRA was significantly greater 
(p < 0.05) in piglets receiving supplemental creatine compared to those receiving Base + 
GAA and Adequate Arg & Met treatments. On the other hand, hepatic creatine SRA was 
significantly greater (p < 0.05) in piglets receiving Adequate Met + GAA compared to 
piglets receiving Base + Creatine. Hepatic SRA of PC and SAM were both significantly 
greater in piglets supplemented with adequate methionine in comparison to low 
methionine treatments (p < 0.05). 
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Table 3.6: Hepatic SRA of Transmethylated Products 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Hepatic Product 
Free Methionine 0.4 ± 0.1a 0.5 ± 0.2a 0.5 ± 0.3a 1.5 ± 0.4b 1.3 ± 0.4b 
Bound Methionine 8.6 ± 4.6ab 7.2 ± 2.1a 15.4 ± 5.1b 8.1 ± 4.4a 11.1 ± 3.2ab 
Creatine 10.9 ± 5.3ab 11.5 ± 2.2ab 6.7 ± 1.3a 9.3 ± 2.2ab 17.1 ± 9.1b 
PC 5.1 ± 3.8a 3.4 ± 1.1a 5.6 ± 2.4a 16.1 ± 3.4b 14.0 ± 2.7b 
DNA 0.7 ± 0.1 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.3 1.1 ± 0.5 
SAM 0.5 ± 0.3a 0.5 ± 0.1a 0.4 ± 0.2a 3.1 ± 0.6b 2.6 ± 0.4b 
 
Data represent means ± standard deviations in DPM/nmol, except for DNA (DPM/µg). 
Bound methionine analysis (n=5).  One-way ANOVA followed by Tukey’s multiple 
comparisons (p < 0.05) were used to test for differences among diets. Means not sharing a 
superscript letter within a row were different.  
Arg, Arginine; DNA, deoxyribonucleic acid; GAA, Guanidinoacetic acid; Met, 
Methionine; PC, Phosphatidylcholine; SAM, S-adenosyl methionine. 
 
 
3.6.2.2 Hepatic Fractional Synthesis Rate (FSR) of Transmethylated Products 
 Hepatic FSR of protein was significantly greater in piglets supplemented with 
creatine compared to all treatments (p < 0.05), except Base Diet (Table 3.7). The hepatic 
FSR of transmethylated products were calculated using the SRA of SAM as the precursor. 
The FSR of creatine and PC synthesis was significantly greater in piglets fed diets 
supplemented with adequate methionine compared to low methionine treatments (p < 
0.05). 
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Table 3.7: Hepatic FSR of Protein and Transmethylated Products 
Treatment 
 Base Base + GAA Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Hepatic Product 
Protein 1.78 ± 0.72ab 0.60 ± 0.41a 3.27 ± 1.66b 0.91 ± 0.50a 1.21 ± 0.82a 
Creatine 11.85 ± 2.84a 12.21 ± 5.82a 10.48 ± 5.68a 28.07 ± 1.86b 27.69 ± 2.09b 
PC 0.87 ± 0.75a 0.75 ± 0.52a 1.14 ± 0.83a 4.18 ± 0.55b 3.69 ± 0.63b 
DNA 0.05 ± 0.01a 0.06 ± 0.03a 0.05 ± 0.02a 0.08 ± 0.03ab 0.11 ± 0.05b 
 
Data represent means ± standard deviations in %/h. Hepatic FSR of Protein (n=5) for 
Base, Base + GAA and Base + Creatine. One-way ANOVA followed by Tukey’s 
multiple comparisons (p < 0.05) were used to test for differences among diets. Means not 
sharing a superscript letter within a row were different.  
Arg, Arginine; DNA, deoxyribonucleic acid; FSR, fractional synthesis rate; GAA, 
Guanidinoacetic acid; Met, Methionine; PC, Phosphatidylcholine. 
 
 
3.6.2.3 Hepatic Distribution of Transmethylated Products 
 After the 6-hour infusion, newly transmethylated hepatic PC from L-[methyl-3H] 
methionine was significantly greater (p < 0.05) in piglets receiving diets with adequate 
dietary methionine compared to other groups (Table 3.8). In piglets receiving low 
methionine diets, hepatic SAM derived from L-[methyl-3H] methionine was significantly 
lower compared to piglets receiving adequate dietary methionine. 
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Table 3.8: 3H-methyl Products Remaining in the Liver After 6 h of L-[methyl-3H] 
Methionine Infusion 
Treatment 
 Base Base + GAA Base + 
Creatine 
Adequate 
Arg & Met 
Adequate Met 
+ GAA 
 
Creatine 108.6 ± 52.7 114.7 ± 22.4 66.9 ± 13 92.6 ± 22 171 ± 91.4 
DNA 8.5 ± 0.8 8.5 ± 1.8 8.4 ± 1.2 7.2 ± 3.7 10.7 ± 3.6 
PC 135.7 ± 85.8a 107.2 ± 59a 142.3 ± 45a 491.2 ± 156b 425.1 ± 116.6b 
Tissue Bound 85.6 ± 45.7 71.5 ± 24.1 153.8 ± 50.5 80.5 ± 43.9 111.1 ± 32.4 
Tissue Free 4.5 ± 1.2 4.7 ± 1.8 4.7 ± 2.6 14.6 ± 4.0 13.1 ± 4.1 
SAM 4.9 ± 2.6a 4.6 ± 1.4a 4.3 ± 1.7a 31.3 ± 5.5b 26.0 ± 4.4b 
 
Data represent means ± standard deviations in x 1000 DPM/g. One-way ANOVA 
followed by Tukey’s multiple comparisons (p < 0.05) were used to test for differences 
among diets. Means not sharing a superscript letter within a row were different. 
Arg, Arginine; DNA, deoxyribonucleic acid; DPM, disintegrations per minute; GAA, 
Guanidinoacetic acid; Met, Methionine; PC, Phosphatidylcholine; SAM, S-adenosyl 
methionine. 
 
 Across all treatment groups, approximately 25% of dietary methionine was 
incorporated into protein and approximately 75% was used for transmethylation reactions 
(Table 3.9). Interestingly, when adequate methionine and arginine were fed, almost 70% 
of dietary methionine was used for synthesis of hepatic PC, while only ~12% was used 
for incorporation into protein. On the other hand, when piglets received supplemental 
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creatine, approximately 40% of methionine was used for incorporation into protein, 
despite receiving limited dietary methionine. 
 
Table 3.9: Proportion of 3H-methyl Products Remaining in the Liver After 6 h of L-
[methyl-3H] Methionine Infusion 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
 
Creatine 31.2 ± 
15.1ab 
39.5 ± 7.7a 18.9 ± 3.7b 13.4 ± 3.2b 23.9 ± 12.8ab 
DNA 2.5 ± 0.2a 2.9 ± 0.6a 2.4 ± 0.3a 1.0 ± 0.5b 1.5 ± 0.5b 
PC 39.0 ± 
24.7ab 
37.0 ± 20.4a 40.1 ± 12.7ab 71.1 ± 22.6b 59.4 ± 16.3ab 
Tissue Bound 24.6 ± 
13.2a 
24.7 ± 8.3ab 43.4 ± 14.2b 11.4 ± 4.9a 15.5 ± 4.5a 
Tissue Free 1.3 ± 0.4 1.6 ± 0.6 1.3 ± 0.7 2.1 ± 0.6 1.8 ± 0.6 
SAM 1.4 ± 0.7a 1.6 ± 0.5a 1.2 ± 0.5a 4.5 ± 0.8b 3.6 ± 0.6b 
Total 
Measured  
3H-Products 
347.8 ± 
118.0a 
290.1 ± 
75.6a 
354.7 ± 
71.7a 
691.6 ± 
151.9b 
715.7 ± 
117.3b 
 
Data represent means in (% of total measured 3H-Products). Total measured 3H-products 
represented in (x1000 DPM/g) (± standard deviations). One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences between diets. 
Means not sharing a superscript letter within a row were different.  
 Arg, Arginine; DNA, deoxyribonucleic acid; GAA, Guanidinoacetic acid; Met, 
Methionine; PC, Phosphatidylcholine; SAM, S-adenosyl methionine. 
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3.6.3 Muscle Methionine Kinetics 
3.6.3.1 SRA of Methionine and Creatine in Muscle 
 Piglets receiving adequate arginine and methionine had significantly greater (p < 
0.05) SRA of free methionine in the muscle compared to piglets receiving low arginine 
and methionine Base diet after 5 days of treatment. Moreover, piglets receiving adequate 
arginine and methionine had significantly greater (p < 0.05) creatine SRA in muscle 
compared to piglets receiving low arginine and methionine, as well as piglets receiving 
supplemental creatine (Table 3.10); piglets with supplemental creatine also had lower 
muscle SRA than Adequate Met + GAA and Base + GAA diets. 
 
Table 3.10: SRA of Methionine and Creatine in Muscle 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Muscle Metabolites 
Free Methionine 11.1 ± 
9.7a 
14.1 ± 
10.7ab 
21.3 ± 
12.2ab 
33.1 ± 
16.8b 
25.8 ± 
12.3ab 
Bound 
Methionine 
1.7 ± 0.4 1.6 ± 0.4 1.8 ± 0.3 1.3 ± 0.4 1.4 ± 0.3 
Creatine 1.3 ± 0.3ab 2.1 ± 0.7bc 0.9 ± 0.3a 2.6 ± 0.5c 2.0 ± 0.6bc 
 
Data represent means standard deviations in DPM/nmol. One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Means not sharing a superscript letter within a row were different.  
Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine. 
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3.6.3.2 Fractional Synthesis Rate of Muscle Protein Synthesis 
 Fractional synthesis rate of protein synthesis in the muscle was not different 
among treatment groups after 5 d of treatment (Figure 3.6). 
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Figure 3.6: Fractional Synthesis Rate (FSR) of Muscle Protein (%/h) 
Bars represent means ± standard deviations in %/h. One-way ANOVA followed by 
Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
No differences among groups were observed. 
Adeq, Adequate; Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
 
3.7 Kidney Creatine and GAA Concentrations 
 Kidney concentrations of creatine were significantly higher (p < 0.05) in piglets 
receiving Adequate Met + GAA compared to piglets receiving Adequate Arg & Met 
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(Table 3.11). Kidney concentrations of GAA were greatest in Adequate Arg & Met 
piglets (p < 0.05) compared to all other treatments. Moreover, piglets receiving the Base 
+ GAA diet had significantly greater renal GAA concentrations compared to piglets 
supplemented with creatine (p < 0.05). 
 
Table 3.11: Kidney Metabolite Concentrations after 5 d of Treatment 
Treatment 
 Base Base + GAA Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + GAA 
Kidney Metabolites 
Creatine* 7.11 ± 3.68ab 6.02 ± 1.73ab 7.50 ± 1.39ab 4.12 ± 1.14a 8.59 ± 2.68b 
GAA* 1.81 ± 0.21ab 2.83 ± 1.00b 1.29 ± 0.23a 4.13 ± 0.70c 1.95 ± 0.71ab 
 
Data represent means ± standard deviations in µmol/g of tissue. One-way ANOVA 
followed by Tukey’s multiple comparisons (p < 0.05) were used to test for differences 
among diets. Means not sharing a superscript letter within a row were different.  
Arg, Arginine; GAA, Guanidinoacetic acid; Met, Methionine 
* Analyses performed by another graduate student, Alaa Al-Jaroudi 
 
3.8 Kidney & Hepatic Enzymatic Activity 
 Hepatic GAMT activity was not different among treatment groups (Table 3.12). 
Renal AGAT activity was significantly greater (p < 0.05) in piglets receiving the 
treatment Adequate Arg & Met compared to piglets receiving Base + GAA, Base + 
Creatine and Adequate Met + GAA diets. Moreover, AGAT activity in the pancreas was 
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also significantly higher (p < 0.05) in piglets receiving Adequate Arg & Met compared to 
piglets supplemented with creatine. 
 
Table 3.12: Enzyme Activities of AGAT and GAMT after 5 d of Treatment 
Treatment 
 Base Base + 
GAA 
Base + 
Creatine 
Adequate 
Arg & Met 
Adequate 
Met + 
GAA 
Enzymatic Activity 
Kidney AGAT* 239 ± 61ab 170 ± 50a 151 ± 56a 364 ± 139b 214 ± 109a 
Pancreas AGAT* 838 ± 228ab 891 ± 122ab 642 ± 152a 980 ± 127b 855 ± 226ab 
Hepatic GAMT 61.9 ± 23.3 48.4 ± 16.9 38.3 ± 26.8 59.0 ± 28.4 74.9 ± 37.4 
 
Data represent means ± standard deviations in nmol/min/g. One-way ANOVA followed 
by Tukey’s multiple comparisons (p < 0.05) were used to test for differences among diets. 
Means not sharing a superscript letter within a row were different.  
AGAT, arginine:glycine amidinotransferase; Arg, Arginine; GAA, Guanidinoacetic acid; 
GAMT, guanidinoacetate methyltransferase; Met, Methionine.  
* Analyses performed by another graduate student, Alaa Al-Jaroudi 
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4. Discussion 
 The methionine requirement during TPN has been demonstrated to be 70% of the 
enteral requirement in the presence of excess cysteine (Shoveller et al., 2003b). 
Moreover, arginine concentrations in parenteral solutions range from as high as 12.3 
g/100 g amino acids to as low as 4.7 g/100 g amino acids (Vlaardingerbroek et al., 2011). 
PN solutions vary in amino acid concentrations due to using different reference proteins, 
but also may be due to confounding research on the optimum concentrations for 
maximum growth in the neonate. The amount of amino acid necessary for maximum 
growth is also affected by the amino acid demands for synthesis of alternative products. 
For example, in the growing neonatal piglet, the equivalent of approximately 35% of 
dietary methionine and 20% of arginine is required for de novo creatine synthesis 
(Brosnan et al., 2009). To demonstrate the sparing effect of creatine and GAA during 
TPN, methionine and arginine needed to be marginally supplied in the diet so that 
synthesis of metabolic products are not already maximized and spared amino acids have 
no effect. We hypothesized that supplemental creatine and GAA could spare methionine 
and/or arginine for other transmethylation functions and for protein synthesis. The main 
objectives of this study were to quantify the partitioning of methionine among 
transmethylation reactions, and to further quantify the sparing effect of creatine and its 
precursor GAA on these methylation pathways and protein synthesis during TPN. 
 
4.1 Rationale of Treatment Groups 
 Shoveller and colleagues have previously demonstrated that the neonatal 
methionine requirement is estimated at 0.18 g/kg/day during TPN, in the presence of 
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cysteine (Shoveller et al., 2003b). Our group chose to supply 0.10 g/kg/day in our Base 
diet, which supplies approximately 55% of the methionine requirement when cysteine is 
present. This inadequate supply of methionine allowed us to evaluate and better 
demonstrate the effects of spared methionine from supplemental creatine. The oral 
arginine requirement for the neonatal piglet has been estimated at approximately 0.38 
g/kg/day (National Research Council, 1998). Whereas, the TPN requirement for dietary 
arginine has been estimated at approximately 1.0 g/kg/day (unpublished observation); this 
higher requirement with TPN is due to TPN-induced gut atrophy which diminished de 
novo arginine synthesis (Bertolo et al., 2003). We chose to supply 0.55 g/kg/day of 
arginine in our Base diet, which is 55% of the estimated TPN requirement. This 
inadequate supply of dietary arginine allowed our group to evaluate and better 
demonstrate, like methionine, the sparing effect of supplemental creatine and its precursor 
GAA during TPN.  
 Supplemental GAA and creatine were supplied in the diet at levels based on 
previous findings by Brosnan and colleagues (Brosnan et al., 2009). They demonstrated 
that suckling piglets aged 4 to 11 days have a total body creatine accretion rate of 
approximately 0.103 g/kg/day. Therefore, our diets were supplemented with an equivalent 
amount of creatine as monohydrate and our piglets received 0.112 g/kg/day via TPN. 
GAA was provided to achieve the same accretion rate on a molar basis. Therefore, GAA 
was supplemented in the TPN diet so our piglets received 0.093 g/kg/day of GAA. 
However, because GAA that is provided to the liver is rapidly converted to creatine 
without feedback regulation at GAMT (McBreairty et al., 2013), we needed to ensure 
adequate dietary methionine was included in the diet to methylate supplemental GAA and 
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meet needs for protein synthesis. Therefore, a second GAA supplemented group was 
employed with a surplus of methionine. 
 As a positive control, one group of piglets needed to receive adequate amounts of 
arginine and methionine to ensure that all products of these amino acids were 
accommodated, including maximizing creatine and protein syntheses. Therefore, dietary 
arginine and methionine were adequately supplied at a rate of 1.8 and 0.5 g/kg/day, 
respectively, which equates to approximately twice the respective oral requirements. 
 
4.2 Creatine Synthesis and TPN 
 The large demands for arginine and methionine for the synthesis of creatine 
potentially places a substantial burden on the growth of the neonate (Brosnan et al., 
2009). Indeed, when our piglets received adequate dietary methionine and arginine, the 
hepatic FSR of creatine was approximately 175% greater than in those piglets receiving 
an inadequate supply of arginine and methionine. Moreover, piglets receiving 
supplemental GAA with adequate amounts of methionine demonstrated similar hepatic 
FSR of creatine as in pigs receiving adequate dietary methionine and arginine. However, 
the hepatic FSR of creatine was lower in piglets supplemented with GAA receiving low 
methionine, demonstrating that creatine synthesis during GAA supplementation is 
induced only when adequate dietary methionine is provided to furnish the higher 
transmethylation requirements. This facilitated creatine synthesis could have spared 
arginine and/or methionine for growth since we also determined that piglets receiving 
supplemental GAA with adequate methionine had 50% greater weight gain in comparison 
to piglets receiving low methionine and arginine diets, despite no differences in organ 
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weights between treatments. Moreover, 72-hour nitrogen retention in GAA plus 
methionine piglets was similar to those receiving adequate arginine and methionine, 
suggesting GAA can spare arginine for growth. On the other hand, our Base and Base + 
Creatine group were also deficient in methionine, but did not differ in 72-hour nitrogen 
retention from those receiving adequate methionine. These findings warrant further 
investigation, as one would expect a lower nitrogen retention when receiving inadequate 
arginine and methionine in the diet. For our Adequate met + GAA group, the increases in 
hepatic creatine synthesis and overall growth suggest that GAA is the driving force of 
creatine synthesis, but only when adequate dietary methionine is available, while also 
sparing arginine for growth. 
  In the kidney, arginine transfers an amidino group to glycine to form GAA and 
ornithine via the enzyme AGAT (Brosnan & Brosnan, 2016). When supplying adequate 
arginine to the diet AGAT activity was significantly upregulated. As previously 
mentioned, we also demonstrated that supplying GAA to the diet in the presence of 
adequate methionine downregulated AGAT and GAA synthesis, but upregulated creatine 
synthesis via GAMT, and can therefore spare arginine for protein synthesis. On the 
contrary, our FSR data did not support greater arginine incorporation into protein. The 
FSR of muscle protein synthesis showed no differences among treatments. And hepatic 
FSR was not different than the Base diet for either GAA group, whether supplemented 
with additional methionine or not. The only group with higher hepatic protein FSR was in 
piglets supplemented with creatine, which at first glance suggests methionine might have 
been spared by creatine to synthesize protein. However, the positive control group with 
higher methionine levels did not have higher hepatic protein FSR. These findings warrant 
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further investigation as one would presume a higher nitrogen retention and weight gain 
would equate to a higher rate of protein synthesis. On the other hand, because a 
methionine tracer was used with varying methionine intakes, perhaps an alternative tracer 
could have been utilized to more accurately measure protein synthesis. In future studies, a 
methionine tracer should be used to quantify transmethylation reactions and another 
tracer, phenylalanine, should be used to quantify protein synthesis.  
 
4.3 Methionine Metabolism and TPN  
 Methionine is the single essential sulfur-containing amino acid and plays a major 
role directly and indirectly in many transmethylation reactions in the neonate (Finkelstein 
et al., 1988). In the cell, methionine is adenylated to SAM via the enzyme MAT and 
transfers its methyl group via many methyltransferases. Indeed, when our piglets received 
adequate dietary methionine the hepatic concentration and SRA of SAM was significantly 
greater in comparison to those receiving inadequate methionine. Whether this significant 
increase in the SRA of SAM suggests an increase in overall transmethylation was not 
determined, although total methyl tracer in creatine, PC and DNA (Table 3.8) suggests 
that higher dietary methionine led to more methylation of these major transmethylation 
products. Another indicator commonly used as a transmethylation index is the SAM:SAH 
ratio (Rowling et al., 2002). A lower SAM:SAH ratio suggests a higher transmethylation 
rate. Our results would suggest that piglets receiving inadequate dietary methionine had a 
higher rate of transmethylation. This is because the SAM:SAH ratio is likely dictated by 
the dietary supply of methionine. Therefore, it is difficult to compare the SAM:SAH ratio 
of piglets receiving variable amounts of dietary methionine and this indicator was in 
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direct contrast to the tracer incorporation data into the two most abundant transmethylated 
products, creatine and PC. 
 
 PC is synthesized via two major pathways: the CDP-choline pathway, also known 
as the Kennedy pathway and the PEMT pathway (Cole et al., 2012). PEMT activity is 
localized to the liver and contributes approximately 30% of total PC and is SAM-
dependent (Reo et al., 2002; Sundler & Akesson, 1975). Our treatments demonstrated that 
during TPN, PC synthesis was approximately 400% greater in piglets receiving adequate 
methionine in comparison to those groups receiving inadequate dietary methionine. It is 
possible that this finding indicates that the synthesis of PC via PEMT relies on the supply 
of dietary methionine. Although the synthesis of PC was significantly upregulated for 
piglets receiving adequate methionine in comparison to those receiving inadequate dietary 
methionine, we did not observe a difference in total hepatic PC concentrations between 
treatments. A definitive reason for this finding cannot be explained but there are several 
possible explanations. Firstly, as previously explained, PC synthesis via the PEMT 
pathway only contributes approximately 30% of the total PC pool and the other 70% of 
PC synthesis via the Kennedy Pathway was not investigated (Cole et al., 2012). It is 
possible that the Kennedy and PEMT pathways work synergistically to establish the 
required amount of PC needed by neonates (Vance et al., 2007). Secondly, the piglets 
received TPN for 7 days which contains Intralipid (Appendix IV). Intralipid is high in PC 
and so these piglets may have been receiving adequate PC via TPN leading to a maximal 
concentration of PC in the liver, thereby masking potential effects of our treatments.  
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4.4 Methionine Partitioning and TPN 
 Methionine plays a major role in transmethylation reactions which include, but are 
not limited to, creatine biosynthesis, DNA methylation, and phosphatidylcholine 
synthesis (Bertolo & McBreairty, 2013). Quantification of partitioning of methionine 
among these major transmethylation reactions and to protein synthesis was a major 
objective in our study. Estimates of the distribution of methionine among the many 
transmethylation reactions vary widely in the literature with few data in neonates (Bertolo 
& McBreairty, 2013; Mudd & Poole, 1975; Noga & Vance, 2003). It has been previously 
found that variations in dietary methionine change the partitioning of  available 
methionine (Bertolo & McBreairty, 2013). Indeed, similar to orally fed piglets, variations 
in parenterally fed methionine in our treatment groups changed the partitioning of 
available methionine. When piglets received adequate dietary methionine, a large portion 
(i.e. ~60%) of dietary methionine was used for PC synthesis and only ~15% for creatine 
synthesis. On the other hand, when piglets received inadequate dietary methionine during 
TPN, available methionine was equally distributed between PC and creatine synthesis, at 
approximately 35% each. These findings are similar to those of previous work in our 
laboratory. When piglets receive inadequate dietary methionine, a large portion of 
available methionine is used for creatine synthesis, which seems to be prioritized over PC 
when methionine is limiting. When excess dietary methionine is fed, a larger percentage 
of methionine is partitioned to PC synthesis. 
 
 Interestingly, supplementation with creatine or GAA also altered the partitioning 
of available methionine. In piglets fed inadequate dietary methionine, supplemental 
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creatine led to a lower percentage of methionine used for creatine synthesis, concomitant 
with an increase in methionine incorporation into protein. This was hypothesized, as 
providing dietary creatine was expected to decrease the need for creatine synthesis and 
spare methionine for other products. These findings paralleled the hepatic FSR data for 
creatine and protein syntheses.   
 
 On the other hand, when our piglets received supplemental GAA with adequate 
dietary methionine, we observed an increase in partitioning of available methionine for 
creatine synthesis, with almost a 2-fold higher partitioning of available methionine to 
creatine compared to piglets receiving adequate arginine and methionine. However, the 
response was not observed when comparing GAA supplementation in piglets receiving 
inadequate dietary methionine, where ~one-third of methionine ended up in creatine in 
both groups. These findings further demonstrate that GAA is the driving force of creatine 
synthesis during TPN, but only when adequate methionine is provided 
 
4.5 Amino Acid Metabolism and TPN 
 In other studies, GAA has been shown to be as effective as creatine in sparing 
arginine for growth, especially when arginine is deficient in the diet (Almquist et al., 
1941; Dilger et al., 2013). Whether GAA can spare arginine for growth and other 
metabolic processes during TPN has yet to be explored. Plasma concentrations of 
metabolites were analyzed and compared across treatment groups. No surprisingly, we 
found that piglets supplemented with inadequate arginine had lower plasma arginine and 
ornithine concentrations, and higher citrulline concentrations, than piglets receiving 
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adequate dietary arginine. The significant decrease in plasma ornithine indicates that an 
inadequate supply of dietary arginine impaired the urea cycle for normal function. Plasma 
glutamine was significantly elevated in piglets receiving inadequate dietary arginine, 
likely to remove excess ammonia which accumulates with arginine deficiency and a 
slower urea cycle (Brunton et al., 1999); glutamine is readily synthesized from ammonia 
and glutamate via glutamine synthase. These same trends were observed when analyzing 
the hepatic free amino acid concentrations. Interestingly, among the inadequate arginine 
groups, GAA or creatine did not change this pattern, suggesting that neither GAA nor 
creatine spared arginine for the urea cycle.  
 
4.6 Future Directions and Conclusion  
 The varying concentrations of amino acids in commercially available TPN can be 
attributed to the different reference proteins used, but also to confusing evidence in the 
literature as to the optimal amino acids profile required for TPN-fed neonates. Therefore, 
it is important to understand the metabolic roles of methionine and arginine in the 
neonatal model, as well as the effectiveness of using primary products of these amino 
acids (i.e., creatine and GAA) to spare them for protein synthesis and growth. In this 
study, we intended to quantify the partitioning of methionine to protein and major 
transmethylation reactions and to determine the sparing effect of creatine and its 
precursor GAA on these pathways.  
  
 In the neonate, TPN causes atrophy of the gut which diminishes arginine synthesis 
and compromises arginine metabolism. Providing GAA, a precursor of creatine and 
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product of arginine metabolism, during TPN seems to relieve this stress and promote 
growth in the neonatal piglet model. Although the present study produced confounding 
results between growth and protein synthesis, there appears to be strong evidence to 
support the finding that GAA is the force driving creatine synthesis. We conclude that 
GAA supplementation during TPN can drive creatine synthesis and spare arginine for 
growth, but only when adequate dietary methionine is provided to ensure enough labile 
methyl groups are available for creatine synthesis. A potential strategy to further increase 
growth and ensure proper remethylation is to provide other dietary remethylation 
precursors during TPN in excess, such as betaine, choline or folate. This will further 
increase methionine availability for creatine synthesis and methionine incorporation into 
protein.   
  
 Higher PC synthesis was expected in our piglets receiving adequate dietary 
methionine, as was demonstrated by the greater hepatic FSR of PC in groups fed more 
methionine. To our surprise, however, hepatic concentrations of total PC did not differ 
between treatments. Although, because PC is synthesized via two major pathways, the 
PEMT and CDP-Choline pathway, future studies should measure both major PC synthesis 
pathways to determine if this higher PC synthesis via PEMT actually translates to more 
total PC for the piglet. Measuring activity of both pathways will allow us to determine if 
both pathways work synergistically during TPN. Using isotope kinetics approaches with a 
labelled choline can help determine the activity of the CDP-choline pathway. 
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 In conclusion, TPN has provided many low birthweight infants with an increased 
chance of survival. It has re-innovated how gut and intestinal disease are treated. 
Ensuring that the optimum nutritional intake is received during these times of distress is a 
major objective of such research. The first step in reaching this goal is ensuring the amino 
acid requirements of the neonate are met and that these requirements include all products 
of amino acids, and not just protein. Elevated concentrations of GAA may be particularly 
neurotoxic in infants. These finding arises from the comparison of outcomes seen in 
infants suffering from AGAT deficiency and GAMT deficiency with elevated 
concentrations of GAA. Before moving forward in the clinical setting, GAA’s possible 
neurotoxic effects should be established or disputed. With that being said, results from 
this study suggest that supplemental GAA could be considered as a novel TPN ingredient 
to increase the synthesis of creatine and spare arginine for growth.  
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Appendices 
Appendix I: D-Glucose & Major Minerals in Complete Elemental and Treatment 
Diets 
 g/L 
D-Glucose 90.3 
Trihydrate K2HPO4 1.57 
Monobasic KH2PO4 0.85 
Potassium Acetate 1.09 
NaCl 2.17 
MgSO4 0.78 
ZuSO4 0.089 
Calcium Gluconate 6.41 
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Appendix II: Trace Mineral Concentrations in Complete Elemental and Treatment 
Diets 
Elemental Name Supplied Mineral 
Formula 
Dose (mg/kg 
BW/day) 
Amount Supplied 
(g/L diet) 
Zinc ZnSO4.7H2O 10.09 40.78 
Copper CuSO4.5H2O 0.86 3.12 
Manganese MnSO4.H2O 0.66 1.89 
Chromium CrCl3.6H2O 0.01 0.05 
Selenium SeO2 0.05 0.06 
Iodine NaI 0.02 0.02 
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Appendix III: Commercial Pediatric IV-Multi-Vitamin Mixture 
Vial 1 Vitamin   
 Amount per 4 mL Dose (per kg BW/day) 
Ascorbic Acid (Vitamin C) 80 mg 17.41 
Palmitate (Vitamin A) 2300 IU 500.48 
Cholecalciferol (Vitamin 
D3) 
400 IU 87.04 
Thiamine (Vitamin 
B1/hydrochloride form) 
1.2 mg 0.26 
Riboflavin (Vitamin 
B2/riboflavin-5-phosphate 
sodium) 
1.4 mg 0.30 
Pyridoxine HCl (Vitamin 
B6) 
1 mg 0.22 
Niacinamide 17 mg 3.70 
Dexapanthenol (d-
panthenyl alcohol) 
5 mg 1.1 
dl-a-tocopherol acetate 
(Vitamin E) 
7 IU 1.52 
Vitamin K1 0.2 mg 0.04 
 
Inactive Ingredients: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid 
to adjust pH. 
 
Vial 2 Vitamin   
 Amount per 2 mL Dose (per kg BW/day) 
Biotin 140 µg 4.35 
Folic Acid 20 µg 30.46 
Cyanocobalamin (Vitamin 
B12) 
1 µg 0.22 
 
Inactive Ingredients: 75 mg mannitol, citric acid and/or sodium citrate to adjust pH. 
Procedure: Vial 1 and 2 were mixed just prior to delivery to animals. To deliver vitamin 
mixture, a total of 3 mL was added to each 750 mL diet bag. 
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Appendix IV: Commercial IV Fat Emulsion (Baxter Intralipid 20%) 
 Percent (%) 
Soybean oil* 20 
Egg yolk Phospholipids** 1.2 
Glycerin 2.25 
 
* Consists of linoleic acid (44-62%), oleic acid (19-30%), palmitic acid (7-14%), a-
linolenic acid (4-11%) and stearic acid (1.4-5.5%). 
** Consists of phosphatidylcholine and phosphatidylethanolamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 106	
 
Appendix V: Composition of the Prime and Constant Dose for Stable Isotopes  
(Tracer study conducted by A. Al Jaroudi) 
Stable Isotope Prime (mg/kg) Constant (mg/kg/h) 
L-arg-13C6-HCl 3.64 6.07 
Guanidineacetic-2,2-D2 0.61 1.02 
Creatine-D3-H2O (Methyl D3) 1.50 1.5 
L-[ring-D5]-Phenylalanine 1.09 3.4 
L-[ring D4]-tyrosine 0.51 NA 
L-[ring 3, 5 D2]-tyrosine 0.50 1.65 
 
